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Summary 
 
Breast cancer is the most common cancer in women worldwide and the second most 
common cancer overall. The most aggressive and most lethal form of breast cancer 
is inflammatory breast cancer (IBC). The mechanisms underlying the aggressiveness 
of IBC are still poorly understood. 
A key feature in the development and progression of breast cancer is the tumor 
microenvironment that is, amongst others, characterized by a specific composition of 
the extracellular matrix (ECM) and by the occurrence of tissue hypoxia and oxidative 
stress. Due to vascular remodeling, leading to structurally and functionally abnormal 
tumor vessels, tumor cells are exposed to alternating periods of hypoxia and 
reoxygenation, called chronic intermittent hypoxia (CIH). CIH is a cause of increased 
reactive oxygen species (ROS) production and has been identified as an important 
factor in promoting tumor progression and metastasis. However, the molecular 
mechanisms through which CIH increases the aggressiveness of breast cancer still 
need to be elucidated.  
Here, we aimed to assess the impact of CIH on gene expression and cancer cell 
malignant properties in IBC and non-IBC cell lines. The triple-negative IBC cell line 
SUM149PT and the estrogen receptor-positive cell line T47D were exposed to 20 
cycles of intermittent hypoxia (24 h 0.2% O2, 48 h 21% O2). The effects of CIH on the 
transcriptomic profile were analyzed in order to obtain insights into signaling 
pathways, which might be involved in the repeatedly reported enhancement of tumor 
aggressiveness upon CIH. CIH caused distinct changes in gene expression in both 
cell lines, with a much higher number of differentially expressed genes in SUM149PT 
cells compared to T47D cells. In T47D cells, we positively validated the differential 
gene expression of two ECM proteins which have been linked to tumor progression. 
In SUM149PT cells, CIH caused a strong upregulation of pro-metastatic genes 
encoding ECM proteins and inflammatory mediators. We positively validated the CIH-
mediated increased mRNA and protein expression of the ECM protein tenascin-C 
(TNC), a key factor in tumor progression. Additionally, for the first time we identified 
an oxidative stress mediated regulation of TNC in IBC cells, which was dependent on 
activation of the NF-κB pathway but not on activation of other redox signaling 
pathways.  
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The observed changes in gene expression suggest an enhanced metastatic 
potential of SUM149PT cells. Performing in vitro assays to analyze the cancer cell 
malignant properties, we observed a trend towards a differential attachment behavior 
of SUM149PT cells following CIH.  
In summary, this thesis identifies CIH in mediating tumor promotive gene 
expression changes. Furthermore, CIH and oxidative stress may play an important 
role in the constitutive activation of NF-κB in IBC, which has repeatedly been 
described in the literature. 
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Zusammenfassung 
 
Brustkrebs ist die häufigste Krebserkrankung bei Frauen und die zweithäufigste 
insgesamt. Die aggressivste und letalste Brustkrebserkrankung ist das 
inflammatorische Mammakarzinom (IBC). Die der IBC Aggressivität zugrunde 
liegenden Ursachen sind weitgehend unbekannt. 
Das Tumormikromilieu ist ein wichtiger Faktor in der Entwicklung und Progression 
von Brustkrebs. Es ist unter anderem durch eine bestimmte Zusammensetzung der 
extrazellulären Matrix (ECM) und durch das Auftreten von Gewebehypoxie und 
oxidativem Stress ausgezeichnet. Krebszellen sind alternierenden Phasen der 
Hypoxie und Reoxygenierung ausgesetzt, auch chronisch intermittierende Hypoxie 
(CIH) genannt. Diese resultiert aus dem Vorhandensein von strukturell und 
funktionell abnormalen Tumorgefässen und aus der Hypoxie-vermittelten 
Angiogenese. CIH generiert reaktive Sauerstoffspezies (ROS) und ist ein wichtiger 
Faktor, welcher die Tumorprogression und Metastasenbildung fördert. Die 
molekularen Mechanismen, durch welche CIH die Tumoraggressivität verstärkt, 
müssen noch aufgeklärt werden. 
Das Ziel unserer Untersuchungen war es, den Effekt von CIH auf die Genexpression 
und die malignen Eigenschaften von IBC und nicht-IBC Zelllinien zu untersuchen. 
Die triple-negative IBC Zelllinie SUM149PT und die Estrogenrezeptor-positive 
Zelllinie T47D wurden für 20 Zyklen intermittierender Hypoxie (24 h 0.2% O2, 48 h 
21% O2) ausgesetzt. Der Effekt von CIH auf die Genexpression wurde analysiert um 
eine Einsicht in die Signalwege zu bekommen, welche bei der wiederholt 
beobachteten Verstärkung der Tumoraggressivität durch CIH involviert sein könnten. 
CIH verursachte Zelllinien-spezifische Veränderungen der Genexpression, wobei 
SUM149PT Zellen eine höhere Anzahl verschieden regulierter Gene aufwiesen als 
T47D Zellen. Für T47D Zellen haben wir die differenzielle Genexpression zweier 
ECM Proteine, welche bekanntermassen mit der Tumorprogression assoziiert sind, 
positiv validiert. In SUM149PT Zellen verursachte CIH eine starke Aufregulierung 
pro-metastatischer Gene, welche für ECM Proteine und Entzündungsmediatoren 
kodieren. Wir validierten die CIH-vermittelten, erhöhten mRNA und Protein Werte 
des ECM Proteins Tenascin-C (TNC), einem entscheidenden Faktor in der 
Tumorprogression. Ausserdem zeigen wir als Erste eine durch oxidativen Stress 
vermittelte Regulierung von TNC in IBC Zellen, welche von der Aktivierung des NF-
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κB Signalweges aber nicht von anderen Redox-regulierten Signalwegen abhängig 
war.  
Die detektierten Veränderungen der Genexpression suggerieren ein erhöhtes 
metastatisches Potential der SUM149PT Zellen. Daher führten wir in vitro 
Experimente durch, um das Krebszellverhalten zu analysieren und fanden ein 
tendenziell verändertes Adhäsionsverhalten nach CIH.  
Zusammengefasst identifiziert diese Dissertation CIH als Verursacher von 
tumorfördernden Veränderungen der Genexpression. Ausserdem könnten CIH und 
oxidativer Stress eine wichtige Rolle für die konstitutive NF-κB Aktivierung im IBC 
spielen, welche wiederholt in der Literatur beschrieben wurde.  
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1. Introduction                                                                                                            
 
1.1 The female breast  
1.1.1 Anatomy of the female breast 
The female breast is a bilateral organ that experiences large changes in shape, size 
and function during infantile growth, puberty, pregnancy, lactation and 
postmenopausal regression (J. Russo & Russo, 2004). The female breast hosts the 
mammary gland, a secretory organ that produces and secretes milk to feed infants. 
Alveoli are the basic components of a mature mammary gland, joining to groups to 
form lobules. Each lobule has a lactiferous duct draining into the nipple (Figure 
1A+B). Epithelial cells of luminal and basal type form the ductal network of the gland. 
The inner luminal epithelium forms the ducts and secretory alveoli and has secretory 
or absorptive functions. The outer basal epithelium consists of myoepithelial cells 
(Watson & Khaled, 2008) which have contractile like properties that assist in milk 
ejection and support of the ductal-lobular system (Figure 1B) (Yoder, Wilkinson, & 
Massoll, 2007). The second predominant tissue in the female breast, next to the 
glandular tissue, is the adipose tissue (Figure 1A). Vascular endothelial cells form the 
blood vessels. Stromal cells, including fibroblasts, and a variety of immune cells are 
further located in the mammary gland (Watson & Khaled, 2008).  
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Figure 1: A) Anatomy of the mammary gland. Lobes (comprising numerous lobules) and ducts drain 
into the nipple and are embedded in the adipose tissue. B) Anatomy of a lobular-ductal unit. The basic 
units of lobules are alveoli consisting of milk-secreting epithelial cells and myoepithelial cells (adapted 
from http://themissionlsc.com/breast-anatomy.html). 
 
1.1.2 Mammary gland development 
The mammary gland development is initiated during the embryonic life. After birth, 
the mammary development halts until puberty. At puberty, growth occurs with the 
elongation of ducts and branching. The development and differentiation of the breast 
are only completed by the end of the first full term pregnancy (J. Russo & Russo, 
2004). During pregnancy, tertiary branches form terminating in alveolar buds (Figure 
2). Further, the luminal epithelium proliferates rapidly and differentiates to the 
secretory alveolar lineage. In the course of late pregnancy, a lactogenic switch 
occurs which is accompanied by the expression of the milk proteins, whey acidic 
protein (WAP) and α-lactalbumin, and by the formation of lipid droplets. Following 
weaning, removal of alveolar cells is accomplished by cell death. During post-
lactational regression (involution), apoptosis leads to removal of about 80% of the 
epithelium within a few days (Watson & Khaled, 2008).  
B
LobeA
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Figure 2: Sequence of changes occurring in the mammary gland during and after pregnancy and 
lactation. (1) Before pregnancy, ducts and alveoli are inactive. (2) In early pregnancy, branching 
occurs. (3) By mid-pregnancy, the secretory alveoli and ducts have dilated lumens. (4) At parturition 
and during the time of lactation, alveoli are greatly dilated and maximally active in production of milk 
components. (5) After weaning, alveoli and ducts regress with apoptotic cell death (Mescher, 2009). 	
 
 
1.2 Breast cancer 
1.2.1 Incidence and risk factors 
Breast cancer is the most common cancer in women worldwide and the second most 
common cancer overall (Ferlay et al., 2015). Its incidence continues to rise, while 
mortality is falling, partially resulting from earlier diagnosis and better therapies. Still, 
20-30% of patients develop metastatic disease that remains incurable. Breast cancer 
metastases cause most of the cancer-related deaths among women (Torre et al., 
2015).  
The risk of breast cancer increases with the age at which a woman bears her first 
child (Rosner, Colditz, & Willett, 1994). An early first full term pregnancy appears to 
be protective, but the involved mechanisms are unknown. A full term pregnancy was 
postulated to inhibit carcinogenic initiation through the induction of differentiation, 
while an undifferentiated and highly proliferating mammary epithelium is a major 
target for carcinogenesis (I. H. Russo & Russo, 1996). This suggests that the breast 
of late parous and nulliparous women might have some of the undifferentiated and 
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cell proliferative characteristics that predispose the tissue to undergo neoplastic 
transformation (J. Russo & Russo, 2004). An additional factor that influences the risk 
of developing breast cancer is the diet. In general, obesity is a risk factor for 
postmenopausal breast cancer (Morimoto et al., 2002), which seems to be largely the 
result of an associated increase in estrogens, particularly bioavailable estradiol 
(Endogenous Hormones Breast Cancer Collaborative Group, 2003). Further, in 
premenopausal women, an increased risk of breast cancer was associated with high 
intake of animal proteins and red meat. On the other hand, high intake of 
polyunsaturated fatty acids, beta-carotene and soya proteins was associated with a 
decreased risk (H. P. Lee et al., 1991).  
Hereditary factors are also involved in breast cancer susceptibility. BRCA1/2, TP53, 
PTEN, LKB1 and CDH1 are prominent genes whose mutations confer a high risk for 
developing breast cancer (Campeau, Foulkes, & Tischkowitz, 2008). Nevertheless, 
environmental factors were postulated to have a higher impact on the risk to develop 
breast cancer than genetic factors (Ziegler et al., 1993). Breast cancer incidence is 
higher in the United States than in China or Japan. However, when Chinese and 
Japanese women migrate to the United States, breast cancer risk rises over several 
generations and approaches that of U.S. whites (Ziegler et al., 1993). 
Much research has been done in the fight against breast cancer but, despite 
huge discoveries and progress in the treatment of breast cancer, we still miss the 
complete understanding of the biologic heterogeneity of breast cancers regarding 
molecular alterations, treatment sensitivity and cellular composition. Hence, breast 
cancer still remains incurable in many cases. 
 
1.2.2 Classification of breast cancer 
Breast cancer is a complex disease with very distinct clinical, morphological and 
molecular entities. It is classified by histopathological type, grade, stage, receptor 
status and gene expression profiles. 
 
1.2.2.1 Histopathological type 
Current histological classification systems of breast neoplasms are based on tumor 
histology and the cell of origin. Breast sarcomas origin from the interlobular stroma 
while mixed fibroepithelial tumors origin from the intralobular stroma (Yoder et al., 
2007). The majorities of breast cancer derive from the epithelium lining the ducts or 
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lobules and are either invasive or non-invasive (in situ). Ductal carcinoma in situ 
(DCIS) and lobular carcinoma in situ (LCIS) are non-invasive, while invasive ductal 
carcinoma (IDC) and invasive lobular carcinoma (ILC) are invasive cancers 
(Peacock, 2001). A rare and very aggressive form of invasive breast cancer is 
inflammatory breast cancer (IBC) (F. M. Robertson et al., 2010).  
 
Inflammatory breast cancer 
IBC is the most aggressive form of breast cancer, with an incidence of up to 5% of all 
breast cancer cases in the United States (Anderson, Schairer, Chen, Hance, & 
Levine, 2005; Hance, Anderson, Devesa, Young, & Levine, 2005). The term 
“inflammatory” origins from its clinical presentation (Haagensen, 1971). IBC is 
characterized by erythema, edema, a “peau d’orange” appearance of the skin, breast 
enlargement, pain and tenderness (F. M. Robertson et al., 2010). IBC progresses 
very rapidly and has a lower overall survival compared to other breast cancers (van 
Uden, van Laarhoven, Westenberg, de Wilt, & Blanken-Peeters, 2015). In 50% of the 
patients, the cancer is not detectable as a palpable mass but rather diffusely 
distributed (W. T. Yang et al., 2008). Because of its very rapid onset of clinical signs 
and symptoms and its “inflammatory” appearance, IBC is often mistaken for a 
bacterial infection (Walshe & Swain, 2005). Almost all patients have lymph node 
metastases and 30% have distant metastases at the time of diagnosis (J. Li et al., 
2011).  
 
1.2.2.2 Grade 
Grading determines the level of differentiation of cancer cells compared to normal 
breast tissue. Carcinomas are divided into low-grade (well differentiated), 
intermediate-grade (moderately differentiated) and high-grade (poorly differentiated), 
as cancer cells progressively loose the features of normal mammary cells (Dervan, 
2001). 
 
1.2.2.3 Stage 
The classification into stages is based on the size of the tumor, whether or not the 
tumor has spread to the lymph nodes, and whether the tumor has metastasized. 
Larger size, nodal spread and metastasis have a larger stage number and a worse 
prognosis (Peacock, 2001). 
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1.2.2.4 Receptor status 
Regarding the receptor status, protein levels of estrogen receptor (ER), progesterone 
receptor (PR) and human epidermal growth factor receptor 2 (HER2) are determined 
in order to stratify patients for prognostic predictions and to select treatments (Khan 
et al., 2015). 
 
1.2.2.5 Molecular subtype 
Perou and colleagues were the first to classify breast cancer into intrinsic subtypes 
based on gene expression profiles. They defined four molecular subtypes: luminal, 
HER2, basal-like and normal breast (Perou et al., 2000). The subsequent expansion 
of this work established six breast cancer intrinsic subtypes: luminal A, luminal B, 
HER2-enriched, claudin-low, basal-like and a normal breast-like group (Prat et al., 
2010; Sorlie et al., 2001). The intrinsic subtype classification provides the most 
valuable biological information on breast cancer. Figure 3 shows the intrinsic 
subtypes of breast cancer and their composition of by receptor status defined clinical 
groups. 
 
                
Figure 3: The intrinsic subtypes of breast cancer and their composition of clinical groups which are 
defined by the receptor status (Prat & Perou, 2011).  
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The intrinsic subtypes are characterized by distinct features (Table 1), such as 
expression levels of pro-proliferative genes, occurrence of specific gene mutations, 
histological tumor grade and prognosis (Figure 4). 
 
Table 1: Features of intrinsic subtypes of breast cancer (adapted from (Eroles, Bosch, Alejandro 
Pérez-Fidalgo, & Lluch, 2012)). 
 
         
Figure 4: Kaplan-Meier relapse-free survival and overall survival curves based on UNC337 data set 
with normal breast-like samples excluded (Prat & Perou, 2011). 
 
Luminal A 
The luminal A breast cancer is with 50-60% the most common subtype. It is 
characterized by the expression of genes that are activated by the estrogen receptor 
(ER) transcription factor and typically expressed in the luminal epithelium lining the 
mammary ducts (Perou et al., 2000; Sorlie et al., 2001). Patients with this subtype of 
cancer have a good prognosis (Kennecke et al., 2010).  
 
Luminal B 
10-20% of all breast cancers are luminal B. They have a more aggressive phenotype, 
higher histological grade and proliferative index and a worse prognosis than luminal 
A-like breast cancers (Kennecke et al., 2010).  
Molecular Subtype Frequency Genes of 
Proliferation 
Histologic 
grade 
TP53 
mutations 
Prognosis 
Basal-like 10-20% High High High Bad 
Claudin-low 12-14% High High High Bad 
HER2-enriched 10-15% High High High Bad 
Luminal A 50-60% Low Low Low Excellent 
Luminal B 10-20% High Intermediate/ 
High 
Intermediate Intermediate/ 
Bad 
Normal breast-like 5-10% Low Low Low Intermediate 
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HER2-enriched 
10-15% of all breast cancers are HER2-enriched. They show a high expression of 
the HER2 gene and other genes associated with the HER2 pathway and/or HER2 
amplicon located in the 17q12 chromosome. These tumors are highly proliferative, 
75% have a high histological grade and more than 40% have p53 mutations. The 
HER2 subtype is characterized by a poor prognosis (Parker et al., 2009; Prat & 
Perou, 2011). 
 
Basal-like 
10-20% of all breast carcinomas are basal-like. Tumors are of large size at diagnosis, 
show a high histological grade and a high frequency of lymph node affectation 
(Bosch, Eroles, Zaragoza, Viña, & Lluch, 2010). The most relevant feature is the 
absence of ER, PGR and HER2 expression. Therefore the terms basal-like and triple 
negative (TN) are often interchanged in clinical practice, even though the terms are 
not equivalent (Kreike et al., 2007). Basal-like tumors have a high rate of p53 (Sorlie 
et al., 2001) and BRCA1 mutations (Sørlie et al., 2003) which could explain their 
enormous aggressiveness and poor prognosis.  
 
Claudin-low 
12-14% of all breast cancers are of the claudin-low subtype. This type of breast 
cancer has its name because of the low expression of genes involved in tight 
junctions and intercellular adhesion, including claudin-3, -4, -7, cingulin, occludin, and 
E-cadherin (Parker et al., 2009; Prat et al., 2010). Claudin-low breast cancers 
overexpress genes closely linked to mesenchymal differentiation and epithelial-
mesenchymal transition which is associated with the acquisition of a cancer stem cell 
(CSC) phenotype (Hennessy et al., 2009; Prat et al., 2010). Claudin-low tumors have 
a poor long-term prognosis (Prat et al., 2010). 
 
Normal breast-like 
5-10% of all breast carcinomas are of normal breast-like. Normal breast-like breast 
cancers are poorly characterized due to their rarity (Perou et al., 2000). There are 
doubts about their existence and some researchers believe them to be a technical 
artifact from high contamination with normal tissue during sample preparation for 
microarrays (Weigelt et al., 2010). 
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1.2.3 Breast cancer metastasis 
Metastasis formation is the malignant tumor growth into secondary organs. Primary 
breast cancer cells metastasize to various distant organs, preferentially to the lung, 
liver and bone (Weigelt, Peterse, & van 't Veer, 2005). Metastasis formation involves 
invasion of carcinoma cells through the basement membrane into the stroma, 
followed by intravasation into lymphatic or blood vessels and systemic dissemination 
(Figure 5). Extravasation into secondary organs is followed by either dormancy or 
activation and colonization, which leads to the formation of a secondary tumor 
(Oskarsson, Batlle, & Massagué, 2014; Scheel & Weinberg, 2012). Basis for these 
processes is the epithelial-to-mesenchymal transition (EMT). EMT is a cellular 
program that confers the biological traits of mesenchymal cells to neoplastic epithelial 
cells. Typical differences between epithelial and mesenchymal cells are observed in 
their morphology, polarity, motility, cytoskeleton composition and specific cell-cell 
adhesion characteristics and result from differential transcription programs. One 
hallmark of EMT is the replacement of E-cadherin by N-cadherin. This results in the 
formation of weaker cell-cell adhesions between adjacent cells and is one feature 
that transmits migratory properties to previously immobile epithelial cells (Ye & 
Weinberg, 2015). At the last step of the metastatic cascade, it has been postulated 
that carcinoma cells switch back to an epithelial state through MET, thereby 
regaining their full proliferative phenotype (Chaffer et al., 2006; Spaderna et al., 
2006).  
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Figure 5: Scheme depicting the steps in the metastatic cascade. Carcinoma cells (blue) undergo EMT 
(changing to red), invade into the stroma (orange) and translocate to distant parenchyma (green). 
During colonization and secondary tumor formation, carcinoma cells are thought to switch back to an 
epithelial state through MET. EMT, epithelial-mesenchymal transition; MET, mesenchymal-epithelial 
transition (Scheel & Weinberg, 2012). 
 
1.2.4 Treatment of breast cancer 
The standard therapies in the treatment of breast cancer are surgery, radiation 
therapy and systemic therapy.  
 
1.2.4.1 Surgery 
One treatment option is the removal of cancerous and potentially affected breast 
tissue by surgery. A total mastectomy includes the total removal of the breast with 
the tumor. A breast-conserving mastectomy is the removal of the breast tumor with 
appropriate margins of the surrounding healthy tissue in a cosmetically acceptable 
manner (Franceschini et al., 2015). 
 
1.2.4.2 Radiation therapy 
Ionizing radiation is used to induce DNA damage and subsequently cellular death (L. 
Li et al., 2016). As cancer cells have a higher proliferation rate than non-cancerous 
cells, there is a higher likelihood that cancer cells are targeted by radiation therapy. 
Radiation therapy can be applied e.g. before mastectomy in order to shrink the tumor 
(neoadjuvant) or following a mastectomy (adjuvant). 
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1.2.4.3 Systemic therapy 
In a systemic therapy, the treatment is taken orally or through intravenous injection to 
reach cancer cells throughout the body. The three general categories of systemic 
therapy used for breast cancer are chemotherapy, hormonal therapy and targeted 
therapy. 
 
Chemotherapy 
Chemotherapy is the administration of drugs targeting rapidly dividing cells by 
interfering with general cell division processes. The currently most common used 
chemotherapeutic agents are anthracyclines and taxanes (Bines, Earl, Buzaid, & 
Saad, 2014). 
 
Hormonal therapy 
The primary female sex hormones regulating diverse physiological processes are 
estrogens. Estrogen signaling is primarily mediated through estrogen receptors (ER) 
α and β, which act as ligand-activated transcription factors binding to estrogen 
response elements (EREs) located within the regulatory regions of target genes 
(Björnström & Sjöberg, 2005; Nilsson et al., 2001). Estrogens are also involved in 
pathophysiological processes, especially in the initiation and progression of breast 
cancer (Yager & Davidson, 2006). More than 50% of all breast cancers overexpress 
ERα and the presence of elevated ERα levels in the benign breast epithelium 
indicates an increased risk of breast cancer (Ali & Coombes, 2000). Most of ERα 
positive breast cancers depend on estrogen signaling for their growth and survival 
(Lappano et al., 2012). Hence, the use of ER antagonists and modulators is the 
primary treatment option for ER positive breast cancers. The most commonly used 
selective estrogen receptor modulator (SERM) is tamoxifen (Vogel et al., 2006). 
 
Targeted therapy 
Genetic alterations and transcriptional deregulations contribute to the initiation and 
development of breast cancer. Therefore, certain types of breast cancers are 
characterized by specific gene mutations or gene amplifications. Hence, novel cancer 
therapies target specific molecular defects that characterize certain cancer cells. This 
increases the treatment efficacy and reduces toxicities, as non-cancerous cells are 
not affected (Livraghi & Garber, 2015). The two main types of targeted therapies are 
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monoclonal antibody therapy and small-molecule therapy. HER2 positive tumors are 
treated with e.g. trastuzumab, an anti-HER2 monoclonal antibody, blocking the effect 
of overexpressed or amplified HER2 molecules (Gerber, 2008). Germline BRCA1 
and BRCA2 mutations are one target in the treatment of BRCA-mutated breast 
cancers. Here, poly(ADP-ribose) polymerase (PARP) inhibitors are used to target 
BRCA-mutated cells following the principle of synthetic lethality (Livraghi & Garber, 
2015). 
 
 
1.3 The tumor microenvironment 
A transformed cell that acquires the capabilities of autonomous proliferation, 
immortalization and invasion does not necessarily lead to the development of cancer. 
Moreover, transformed cells need to arise in an environment that supports the tumor 
development, called the tumor microenvironment (Bhome et al., 2015). The potential 
of cancer cells in forming metastases depends on their capability to facilitate 
favorable changes in the microenvironment of distant organs (Oskarsson et al., 
2014). The tumor microenvironment includes the physicochemical and the cellular 
microenvironment, whereby the composition of the extracellular matrix (ECM) as well 
as tissue oxygenation and oxidative stress are important factors. 
 
1.3.1 The extracellular matrix (ECM) 
The ECM is a non-cellular three-dimensional macromolecular network composed of 
collagens, proteoglycans (PGs), glycosaminoglycans (GAGs), elastins, fibronectins, 
laminins and several other glycoproteins. Matrix components bind each other as well 
as cell adhesion receptors, constituting a complex network (Theocharis, Skandalis, 
Gialeli, & Karamanos, 2015). The ECM provides not only physical scaffolds, also cell 
surface receptors transduce signals from the ECM into the cells, regulating diverse 
cellular functions such as survival, growth, migration and differentiation (Theocharis 
et al., 2015). The ECM also serves as a reservoir for growth factors, cytokines and 
chemokines which can be liberated through cleavage from ECM components 
(Rozario & DeSimone, 2010).  
 
 
 
  Introduction 
	 13	
1.3.1.1 The ECM and cancer 
The extracellular matrix is a major player in cancer progression and metastasis 
(Hynes, 2009). During tumorigenesis, distinct alterations in the ECMs take place, 
leading to the formation of fibrotic stroma with increased stiffness, excessive 
deposition of ECM components and release of proteolytic enzymes which, upon 
activation, result in abnormal ECM remodeling (Theocharis et al., 2015). Proteolytic 
degradation of ECM components is mediated by enzymes, such as matrix 
metalloproteases (MMPs), a disintegrin and metalloproteases (ADAMs), ADAMs with 
thrombospondin motifs (ADAMTSs), cathepsins and plasminogen activators 
(Jarvelainen, Sainio, Koulu, Wight, & Penttinen, 2009).  
 
Breast ducts and lobules are bilayered structures with an inner ring of luminal 
epithelial cells and an outer ring of myoepithelial cells. Myoepithelial cells are 
believed to play an important tumor suppressive role in the healthy breast as their 
presence inhibits invasion of cancer cells into the surrounding stroma (Gudjonsson et 
al., 2002; Ingthorsson, Hilmarsdottir, Kricker, Magnusson, & Gudjonsson, 2015). 
Myoepithelial cells surrounding tumors show a shift in ECM protein secretion, losing 
expression of tumor-suppressive laminins and increasing expression of collagens 
(Allinen et al., 2004; Ingthorsson et al., 2015). Surrounding the ducts and lobules is 
the breast stroma and stromal changes are observed even in the early stages of 
malignancy. This involves the appearance of cancer associated fibroblasts (CAFs), 
the recruitment of various immune cells, enhanced collagen I deposition and 
epigenetic modifications of stromal cells (Rudnick & Kuperwasser, 2012). A tumor 
promotive microenvironment is essential for the process of tumorigenesis (Figure 6) 
and an altered microenvironment can itself become a potent tumor promoter (Bissell 
& Hines, 2011).  
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Figure 6: The tissue microenvironment can suppress or promote tumorigenesis (Bissell & Hines, 
2011). 
 
In breast cancers, high levels of fibronectin and its splice variants, crosslinked 
collagen I and tenascin-C are associated with poorer survival or time to progression 
for breast cancer patients. High levels of laminins, high molecular weight hyaluronic 
acid, heparins, versican, lumican or decorin correlate with better outcomes (C. 
Robertson, 2015). Next to changes in the expression levels of ECM components, 
changes in the spliceosome occur during the progression to malignancy (Venables, 
2004). Here, ECM proteins with alternative splice forms are often observed to 
undergo isotype switching during the development of cancer (Di Modugno et al., 
2012). Malignant cells express much higher levels of ED-A fibronectin and its 
receptor, α5β1 integrin, both of which have been linked to radioresistance (Nam, 
Onodera, Bissell, & Park, 2010). Tenascin-C has also multiple alternative splice 
forms which are not observed in normal adult breast tissue (Adams, Jones, Walker, 
Pringle, & Bell, 2002). Furthermore an increased collagen deposition has been linked 
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to the progression of cancer, whereby invasive breast cancers showed an increased 
expression of fibrillar collagens compared to normal or to DCIS (Schummer et al., 
2010). Fibrillar collagen I has been proposed as a link between increased 
mammographic breast density and increased risk of breast cancer (Martin & Boyd, 
2008). Therefore, manual palpation is an important diagnostic method (Barton, 
Harris, Sw, JAMA 1999;282:1270-1280., & Nusbaum, 2001), whereby stiffness 
appears to increase with increasing tumor grade (Mullen, Thompson, Moussa, 
Vinnicombe, & Evans, 2014), concomitantly predicting a poorer prognosis (Berg et 
al., 2015). Successful chemotherapy has been shown to decrease tumor stiffness, 
whereas stiffening was observed in chemotherapy-resistant tumors (Falou et al., 
2013).  
	 
1.3.2 Hypoxia and intermittent hypoxia  
1.3.2.1 Occurrence and role in tumor progression 
In healthy tissues, the oxygen supply matches the cellular requirements (normoxia). 
Hypoxia occurs when oxygen supply and consumption are not balanced and normal 
cellular functions cannot be maintained. The prevalence of hypoxic tissue areas is a 
feature of solid tumors, whereby hypoxic areas are heterogeneously distributed 
within the tumor mass (Vaupel & Mayer, 2007). Tumor hypoxia gives rise to a more 
malignant phenotype including the occurrence of metastases and it is associated with 
poor patient outcome in several types of cancer (Vaupel & Mayer, 2007). 
Intratumoral hypoxia results from two major mechanisms. Tumor cells frequently 
outgrow their vascular supply territories caused by their abnormal growth patterns 
(Brown & Giaccia, 1998). This leads to a gradient of diffusion-limited oxygen supply 
(Figure 7), where some tumor cells are not sufficiently supplied with oxygen as they 
are in too far distance from the blood vessels (Denko, 2008).  
 
                                         
Figure 7: Diffusion-limited oxygen delivery in solid tumors (Denko, 2008). 
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Since hypoxia initiates angiogenesis, new blood vessels will grow into the hypoxic 
tumor microenvironment (Liao & Johnson, 2007). This enhances the oxygen supply 
and reduces the hypoxic areas until the tumor cells will outgrow this new supply 
again. However, the tumor neovasculature shows severe structural and functional 
abnormalities resulting in a perfusion-limited oxygen delivery that causes fluctuations 
of blood and hence oxygen supply (Figure 8) (Durand & Aquino-Parsons, 2001). 
Therefore, the tumor microenvironment is characterized by cycling periods of hypoxia 
and reoxygenation, also known as intermittent hypoxia (IH) (Dewhirst, Cao, & 
Moeller, 2008). 
 
                  
Figure 8: Comparison of normal vasculature and tumor vasculature. A disorganized tumor vasculature 
can cause a perfusion-limited oxygen delivery (Jain, 2001).  
 
There are two dominant timescales that contribute to the cycling kinetics of IH. 
Vascular remodeling and angiogenesis are responsible for a slow frequency of 
cycling hypoxia (several cycles per day or week) (Bhaskara, Mohanam, Rao, & 
Mohanam, 2012; Cao et al., 2005). Variations in red blood cell flux within tumor 
microvessels can lead to a high frequency of hypoxic cycles (several cycles per hour) 
(Hsieh, 2010; Kimura et al., 1996). 
Most past and current research aimed for the understanding of the role of chronic 
hypoxia in tumor progression and metastasis formation. However, the importance of 
IH is becoming more widely accepted and research on intermittent hypoxia 
increases. Chronic and intermittent hypoxia cause distinct effects, but IH has been 
shown to promote angiogenesis, resistance to anti-cancer treatment, intratumoral 
inflammation and tumor metastasis, to a higher extent than chronic hypoxia (Cairns, 
Normal vasculature Abnormal tumor vasculature
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Kalliomaki, & Hill, 2001; Chou et al., 2012; Hsieh, 2010; Kalliomäki, McCallum, Lunt, 
Wells, & Hill, 2008; Martinive et al., 2006; Tellier et al., 2015)  
The molecular mechanisms causing these phenotypic changes are not well 
elucidated, but main factors might be changes in the regulation of transcription 
factors and changes in gene expression. 
Cells adapt to the hypoxic microenvironment by up-regulating pro-survival 
mechanisms, the majority of which are coordinated by the transcription factor hypoxia 
inducible factor-1α (HIF-1α) (Maxwell, 2001). Further, the oscillating changes in 
tissue oxygenation are widely considered as a source of reactive oxygen species 
(ROS) (Dewhirst et al., 2008; Nanduri, Yuan, Kumar, Semenza, & Prabhakar, 2008). 
Several transcription factors have been reported to be activated by ROS. These are 
nuclear factor (erythroid-derived 2)-like 2 (Nrf2), activator protein-1 (AP-1) and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). 
 
1.3.2.2 Hypoxia inducible factor (HIF) 
Hypoxic conditions lead to the activation of the hypoxia-inducible factor (HIF) 
signaling pathway. The HIF transcription factors are heterodimers composed of an 
oxygen-sensitive regulatory α-subunit (HIF-α) and the constitutively expressed β-
subunit (HIF-1β /ARNT (aryl hydrocarbon receptor nuclear translocator)). HIF α and -
β proteins belong to the basic-helix-loop-helix (bHLH)/Per-ARNT-SIM (PAS) family of 
transcription factors. The bHLH domain mediates DNA-binding, while PAS and bHLH 
domains mediate heterodimerization with HIF-1β (Jiang, Rue, Wang, Roe, & 
Semenza, 1996; Semenza, 1999; G. L. Wang, Jiang, Rue, & Semenza, 1995). Three 
isoforms of the α-subunit existing in mammals, HIF-1α, HIF-2α and HIF-3α 
(Semenza, 2012). HIF-1α and HIF-2α share 48% amino acid sequence identity and 
contain amino- and carboxy-terminal oxygen-dependent degradation domains 
(NODDD and CODDD, respectively), and N-terminal and C-terminal transactivation 
domains (N-TAD and C-TAD). The domain structure of HIF-1α is shown in Figure 9. 
Beside a similar domain architecture, HIF-1α and HIF-2α are regulated in a 
comparable manner (O'Rourke, Tian, Ratcliffe, & Pugh, 1999; Schofield & Ratcliffe, 
2004). HIF-3α is less closely related and its regulation is less well understood. Still, 
HIF-3α contains an ODDD, which includes the consensus oxygen-dependent prolyl 
hydroxylation motif, and can be targeted for ubiquitylation. Further, multiple 
alternatively splice variants have been reported (Maynard et al., 2003). One splice 
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variant is known as inhibitory PAS protein (IPAS). IPAS is composed of the amino-
terminal basic helix-loop-helix and PAS domains, but omits the CODDD and other 
carboxy-terminal sequences. IPAS was shown to form transcriptionally inactive 
heterodimers with HIF-1α, leading to the inhibition of HIF-1α-dependent gene 
expression (Makino et al., 2001).  
 
1.3.2.3 HIF signaling 
The major mechanism for HIF regulation is mediated by enzymatic hydroxylation of 
specific residues in the NODDD, CODDD and C-TAD (Figure 9) (Schofield & 
Ratcliffe, 2004). In normoxia, HIF-α is continuously synthesized and rapidly degraded 
by the ubiquitin-proteasome system (L. E. Huang, Gu, Schau, & Bunn, 1998). 2-
oxoglutarate and iron-dependent di-oxygenases, known as prolyl-4-hydroxylase 
domain (PHD)1, PHD2 and PHD3, hydroxylate HIF-α at two proline residues in the 
NODDD and CODDD (P564 and P402 in human HIF-1α, and P530 and P405 in 
human HIF-2α). These hydroxylations increase the affinity of the von Hippel-Lindau 
tumor suppressor protein (pVHL) for HIF-α (Ivan et al., 2001; Jaakkola et al., 2001). 
VHL forms part of a complex with elongins B and C, Cullin 2 and RING-Box protein 1 
(RBX1) to constitute a functional E3 ubiquitin protein ligase. Subsequent 
polyubiquitination of HIF-α targets it for proteasomal degradation (Iwai et al., 1999). 
Additionally, the asparagine hydroxylase factor inhibiting HIF-1 (FIH-1) hydroxylates 
a specific asparagine residue within the C-TAD (N803 in human HIF-1α and N851 in 
human HIF-2α), preventing the recruitment of the transcriptional co-activators 
p300/CBP (p300 and CREB binding protein) and subsequent transactivation of target 
genes (Lando et al., 2002a; Lando, Peet, Whelan, Gorman, & Whitelaw, 2002b). In 
hypoxia, the activity of PHDs and FIH-1 is reduced, as they require molecular oxygen 
as a co-substrate (Jaakkola et al., 2001; Lando et al., 2002a), HIF-α protein 
accumulates, translocates into the nucleus and dimerizes with HIF-1β to form the 
transcription factor HIF. HIF binds DNA of target genes at hypoxia response 
elements (HREs), recruits p300/CBP and enhances transcription (Wenger, Stiehl, & 
Camenisch, 2005).  
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Figure 9: Domain structure of HIF-1α and its regulation in normoxia and hypoxia. In normoxia, PHDs 
hydroxylate HIF-1α, thereby targeting it for proteasomal degradation. FIH-1 mediated hydroxylation 
prevents cofactor recruitment. In hypoxia, hydroxylation is reduced, HIF-1α protein accumulates, 
translocates into the nucleus, dimerizes with HIF-1β and binds to HREs of target genes. PHD, prolyl-4-
hydroxylase domain; FIH-1, factor inhibiting HIF-1; bHLH, basic-helix-loop-helix domain; PAS: 
Per/ARNT/SIM motif; ODDD: oxygen-dependent degradation domain; N-TAD: N-terminal 
transactivation domain; C-TAD: C-terminal transactivation domain; pVHL, von Hippel-Lindau protein; 
HRE: hypoxia response element (Weidemann & Johnson, 2008). 
 
HIF-1α and HIF-2α have both overlapping and unique biological functions. HIF-1α 
induces gene expression of proteins involved in glycolysis (e.g. lactate 
dehydrogenase A (LDHA)) (Firth, Ebert, & Ratcliffe, 1995), while the control of 
erythropoiesis in vivo seems to be specific to HIF-2α (Rankin et al., 2007; 
Scortegagna et al., 2003), and modulation of angiogenesis is a common function of 
both HIF-1α and HIF-2α (e.g. vascular endothelial growth factor (VEGF)) (Hu, Wang, 
Chodosh, Keith, & Simon, 2003; Y. Liu, Cox, Morita, & Kourembanas, 1995). HIF-1α 
expression can be found in all nucleated cells, while HIF-2α expression seems to be 
restricted to specific cell types (Patel & Simon, 2008). 
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1.3.3 Reactive oxygen species (ROS), redox biology and oxidative stress 
Reactive oxygen species (ROS) are by-products of aerobic metabolism. The most 
well studied ROS in cancer include superoxide anion (O2
-
), hydrogen peroxide 
(H2O2) and hydroxyl radicals (OH) (Lambeth, 2004). ROS are required for various 
biological processes, thereby acting as secondary messengers. As a component of 
the cellular redox biology, small increases in ROS levels can activate signaling 
pathways, thereby initiating biological processes (Finkel, 2011). On the other hand, 
high levels of ROS can cause damage to lipids, proteins and DNA and are therefore 
described as oxidative stress. Oxidative stress has been suggested to induce 
pathologies like cancer (Cross et al., 1987). In order to counteract the detrimental 
effects of ROS cells produce antioxidant reducing cofactors and proteins like reduced 
glutathione (GSH), nicotinamide adenine dinucleotide phosphate (NADPH), 
thioredoxin (Trx), superoxide dismutases (SODs), catalase, glutathione peroxidases 
(GPxs) and peroxiredoxins (Prxs) (Cairns, Harris, & Mak, 2011; Holmström & Finkel, 
2014). 
Rapid proliferation of cancer cells causes high levels of ROS production. Additional 
mutations and adaptations, such as an increase of the antioxidant response, enable 
cancer cells to maintain ROS levels that allow pro-tumorigenic signaling pathways to 
be activated without inducing cell death (Cairns et al., 2011; Hayes & McMahon, 
2009; Tai et al., 2012). 
 
1.3.3.1 Cellular sources of ROS 
There are many cellular sources of reactive oxygen species (ROS) within a cell. The 
electron transport chain in the mitochondria is the major source of ROS, through 
electron leakage from complex I and III (Figure 10A). The electrons react with 
molecular oxygen to produce superoxide. Further mitochondrial enzymes that are 
able to produce ROS are the pyruvate dehydrogenase (PDH), the 2-oxoglutarate 
dehydrogenase (OGDH), the electron transferring flavoprotein ubiquinone 
oxidoreductase (FQR), and the glycerol 3-phosphate dehydrogenase (GPDH) (Figure 
10A) (Brand, 2010). Plasma membrane-bound NAD(P)H oxidases (NOXs) produce 
superoxide upon activation for a range of host defense and signaling functions 
(Figure 10B) (Morgan & Liu, 2011). Another source of ROS is the disulfide bond 
formation during protein folding in the endoplasmic reticulum (ER) (Figure 10C). 
Protein disulphide isomerase (PDI) accepts electrons from protein-folding substrates 
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and the electrons are transferred to molecular oxygen via ER oxidoreductin 1 (ERO1) 
(Tu & Weissman, 2002). Additional enzymes which can produce ROS are xanthine 
oxidase, cyclooxygenases, nitric oxide synthases, cytochrome P450 enzymes and 
lipoxygenases (Holmström & Finkel, 2014). 
 
                          
Figure 10: Cellular sources of ROS. (A) ROS are generated through electron leakage from complex I 
and III in the mitochondrial electron transport chain and through other mitochondrial enzymes. PDH, 
pyruvate dehydrogenase; OGDH, 2-oxoglutarate dehydrogenase; FQR, flavoprotein ubiquinone 
oxidoreductase; GPDH, glycerol 3-phosphate dehydrogenase (Holmström & Finkel, 2014). (B) 
Assembly and activation of the NADPH oxidase (NOX) superoxide-generating complex transfers 
electrons from cytosolic NADPH to molecular oxygen (adapted from Holmström & Finkel, 2014). (C) 
ROS are generated during protein folding. Protein disulphide isomerase (PDI) accepts electrons from 
protein-folding substrates and the electrons are transferred to molecular oxygen via ER oxidoreductin 
1 (ERO1) (adapted from K. Zhang & Kaufman, 2008). 
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Generation of ROS during intermittent hypoxia 
Several studies have reported an increased ROS production during oxygen 
deprivation followed by PHD inactivation and HIF-1α and HIF-2 α protein 
stabilization, whereby the mitochondrial electron transport chain was implicated as 
the major source of ROS (E. L. Bell et al., 2007; Duranteau, Chandel, Kulisz, Shao, & 
Schumacker, 1998; Guzy & Schumacker, 2006; Guzy et al., 2005). While an 
increased ROS production during hypoxia is highly debated, it has been widely 
accepted and studied that reoxygenation leads to ROS production (Littauer & de 
Groot, 1992). Reoxygenation-mediated ROS production was described in different in 
vitro studies, for example using U87 glioma cells or endothelial cells as cellular 
models (Hsieh, 2010; Toffoli et al., 2009). Moreover, reoxygenation has been shown 
to cause ROS-dependent DNA damage in vitro (Hammond, Dorie, & Giaccia, 2003). 
In vivo, reoxygenation that occurs after irradiation has been shown to produce ROS 
(Moeller, Cao, Li, & Dewhirst, 2004).  
The acute reintroduction of oxygen during reoxygenation leads to a burst of ROS 
production that may result from different cellular sources, such as the mitochondrial 
electron transport chain (Holmström & Finkel, 2014). Another source may be the ER 
as unfolded proteins accumulate during hypoxia. Upon reoxygenation, disulfide 
bonds are rapidly introduced, leading to high level of ROS production (Koritzinsky & 
Wouters, 2013). Additionally, different NOX subunits have been shown to be 
inducible by ROS and Hsieh et al. demonstrated that the IH mediated increase of 
intracellular ROS production was dependent on NOX4 (Diebold et al., 2009; 
Djordjevic et al., 2005; Hsieh et al., 2012). Hence, elevated ROS levels following 
reoxygenation may induce the expression of NOX subunits thereby promoting a 
sustained ROS generation under these conditions. Furthermore, NOX2 and NOX4 
have been shown to be HIF-1α target genes (Diebold, Petry, Hess, & Görlach, 2010; 
Diebold et al., 2012; Yuan et al., 2011). Hence, hypoxia may cause increased NOX2 
and NOX4 protein levels, thereby even enhancing the NOX-mediated ROS 
production during reoxygenation.  
 
1.3.3.2 Cysteine biochemistry and redox-dependent signaling 
ROS can mediate changes in signal transduction by oxidative modification of proteins 
(Figure 11). Here, ROS oxidize the sulfhydryl group (SH) in redox-reactive cysteine 
residues resulting in a sulfenic form (-SOH), which can lead to the formation of intra- 
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or intermolecular disulfide bonds (-S-S-). Further oxidation of the sulfenic form results 
in sulfinic (-SO2H) or sulfonic (-SO3H) forms (Roos & Messens, 2011). 
 
                           
Figure 11: Mechanism of ROS mediated cysteine modification. ROS mediated oxidation of cysteine 
residues leads to the formation of the sulfenic form (-SOH), which can either form disulfide bonds or it 
is further oxidized to the sulfinic (-SO2H) or sulfonic (-SO3H) forms (adapted from Finkel, 2011). 
 
1.3.3.3 Role of ROS in signal transduction by targeting phosphatases 
ROS mediated oxidative modifications of phosphatases can cause changes in signal 
transduction. The oxidative modifications result in a differential structure and function 
of the protein. Thereby, protein tyrosine and dual-specificity phosphatases, like 
phosphatase and tensin homolog deleted on chromosome ten (PTEN) or mitogen-
activated protein kinase (MAPK) phosphatases, can be inactivated and downstream 
signaling cascades may be activated (Kwon et al., 2004; S.-R. Lee et al., 2002; 
Salmeen et al., 2003; Seth & Rudolph, 2006).  
The phosphatidylinositol 3 kinase (PI3K)/Akt pathway regulates a wide range of 
cellular processes including cell proliferation, migration and survival (Figure 12) 
(Cantrell, 2001). The tumor suppressor PTEN negatively regulates Akt activity by 
converting phosphatidylinositol-3,4,5-triphosphate (PIP3) into phosphatidylinositol-
4,5-bisphosphate (PIP2) (Maehama, Taylor, & Dixon, 2001). PTEN is often mutated 
in many human cancers and loss of PTEN function has been shown to promote 
survival and proliferation of cancer cells (Cantrell, 2001; Katso et al., 2001). Also the 
ROS-mediated inactivation of PTEN can have pro-survival and pro-proliferative 
ROS
SO H!
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  Introduction 
	 24	
effects by activation of the Akt pathway (Matsuda, 2013; F. Weinberg & Chandel, 
2009).  
 
            
Figure 12: Model of the Akt pathway activation. Stimuli-dependent receptor activation leads to PI3K 
activation. Activated PI3K phosphorylates PI(4,5)P/PIP2 to produce PI(3,4,5)P/PIP3. PDK1 is recruited 
to the plasma membrane and activates Akt, which regulates various cellular processes, such as cell 
survival and proliferation. PTEN negatively regulates Akt activity by dephosphorylating PIP3. PI3K, 
phosphatidylinositol 3 kinase; PI(4,5)P/PIP2, phosphatidylinositol-4,5-bisphosphate;  PI(3,4,5)P/PIP3, 
phosphatidylinositol-3,4,5-triphosphate; PTEN, phosphatase and tensin homolog deleted on 
chromosome ten; PDK1, 3-phosphoinositide-dependent protein kinase 1  (Planchon, Waite, & Eng, 
2008). 
 
Hence, elevated ROS levels in cancer cells can have tumor-promotive effects by 
activation of signaling pathway such as the Akt or MAPK pathways. 
Oxidative modifications are reversible through reducing systems such as the 
thioredoxin system (Roos & Messens, 2011).  
 
1.3.3.4 The thioredoxin system 
An important antioxidant system, which is conserved in all species, is the thioredoxin 
system (Holmgren, 1985). The thioredoxin system includes the proteins thioredoxin 
and thioredoxin reductase. Thioredoxin contains an active site motif of Cys-Gly-Pro-
Cys, and exists either in a reduced form (thioredoxin-(SH)2) with a dithiol, or in an 
oxidized form (thioredoxin-S2) by formation of an intramolecular disulfide bridge 
(Holmgren, 1985). Reduced thioredoxin catalyzes the reduction of disulfide bonds in 
other oxidized proteins. In this process thioredoxin becomes oxidized and a disulfide 
bond forms between the two cysteine residues in its active site (Figure 13). 
  Introduction 
	 25	
Thioredoxin reductase restores thioredoxin to a reduced state with the use of NADPH 
(Holmgren, 1985). Thioredoxin can also directly scavenge reactive oxygen species 
(K. C. Das & Das, 2000) and it further regulates the activity of other important 
enzymes, such as peroxiredoxins (Rhee, Chae, & Kim, 2005), which also maintain 
the cellular redox balance. Peroxiredoxins use their SH groups to reduce peroxides 
such as H2O2, organic hydroperoxides and peroxynitrite (Figure 13). The oxidized 
form of peroxiredoxins is then reversed to the active reduced form by thioredoxin 
(Rhee et al., 2005).  
 
                          
Figure 13: Mechanisms of the thioredoxin (Trx) system. Reduced Trx mediates the reduction of 
disulfides (S-S) within oxidized cellular proteins, like peroxiredoxin (Prx). Trx becomes oxidized, which 
in return is reduced by thioredoxin reductase (TrxR) at the expense of NADPH (adapted from 
Karlenius & Tonissen, 2010). 
 
1.3.3.5 MAPK/AP-1 signaling and its regulation by ROS 
The mitogen-activated protein kinase (MAPK) signaling pathways harbor four major 
MAPKs: the extracellular signal-related kinases (Erk1/2), the c-Jun N-terminal 
kinases (JNK), the p38 kinase (p38), and the big MAP kinase 1 (BMK1/Erk5). Upon 
stimulation by growth factors, hormones, cytokines and also genotoxic and oxidative 
stress, MAPK kinase kinases (MAPKKK) phosphorylate and activate MAPK kinases 
(MAPKK), which in turn phosphorylate and activate MAPKs (Morrison, 2012).  
Activator protein 1 (AP-1) is a transcription factor involved in MAPK signaling that has 
been shown to be regulated by ROS (Chang & Karin, 2001).  AP-1 regulates many 
cellular processes, including cell proliferation, death, survival and differentiation. AP-
1 is a dimer composed of basic-region-leucine zipper (bZIP) proteins that belong to 
the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-2), Maf (c-Maf, MafB, 
MafA, MafG/F/K, Nr1) and ATF (ATF2, LRF1/ATF3, B-ATF, JDP1, JDP2) sub-
families (Shaulian & Karin, 2002). The differential AP-1 dimer composition alters its 
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DNA-binding specificity and determines its molecular function and thus the regulation 
of specific target genes. c-Jun is the most potent transcriptional activator in its group, 
forming stable heterodimers with e.g. Fos proteins (Shaulian & Karin, 2002). During 
tumorigenesis, c-Jun is known as an essential regulator of major cellular processes, 
such as cell proliferation. Jun-Fos dimers were shown to promote proliferation and 
neoplastic transformation (van Dam & Castellazzi, 2001). c-Jun overexpressing cells 
demonstrated higher mobility and invasiveness and loss of polarity in mammary 
epithelial cells (Bos, Margiotta, Bush, & Wasilenko, 1999; Fialka, 1996). 
The regulation of AP-1 activity is complex and occurs at different levels (Shaulian & 
Karin, 2002). Regarding c-Jun/c-Fos dimers, elevation of AP-1 transcriptional activity 
is partly mediated by an enhanced c-Jun phosphorylation on Ser63 and Ser73 
through JNK (Dérijard et al., 1994). This is followed by c-Jun/c-Fos dimerization and 
binding to AP-1 binding sites in the promoter region of target genes. The JUN gene 
has an AP-1 binding site in its promoter region itself. Therefore, activation of the AP-
1 transcription factor leads also to enhanced c-Jun transcription, resulting in a 
positive feedback loop and elevated levels of the c-Jun protein (Figure 14) (Z. Yang 
et al., 2009). 
                                     
Figure 14: Model depicting the JNK mediated phosphorylation of c-Jun, followed by dimerization with 
c-Fos and transcriptional activation of JUN. JNK, c-Jun N-terminal kinase; AP-1, activator protein 1 
(adapted from Z. Yang et al., 2009). 
 
The regulation of MAPK signaling by ROS occurs on different levels. The activation 
of AP-1 by ROS is mediated mainly by JNK and p38 MAPK cascades (Chang & 
Karin, 2001). MAPK pathways can be activated by the direct inhibition of MAPK 
phosphatases by ROS as it was shown for JNK activation (Kamata et al., 2005) and 
p38 activation (Robinson et al., 1999). Moreover, an upstream MAPKKK that 
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regulates the JNK and p38 MAPK pathways is the apoptosis signal-regulated kinase 
1 (ASK1) (Ichijo, 1997; Tobiume et al., 2001). Reduced thioredoxin was shown to 
constitutively interact with ASK1, thereby inhibiting its kinase activity (Figure 15). 
ROS-mediated oxidation of thioredoxin results in dissociation from ASK1, followed by 
ASK1 activation and subsequent activation of JNK or p38 signaling pathways (Saitoh 
et al., 1998).  
                                  
Figure 15: Regulation of ASK1 by ROS. Reduced thioredoxin (Trx) binds and inhibits ASK1. ROS-
mediated oxidation of Trx releases ASK1. Activated ASK1 activates downstream effectors such as 
p38 and JNK. ASK1, apoptosis signal-regulated kinase 1; p38, p38 kinase; JNK, c-Jun N-terminal 
kinase; ROS, reactive oxygen species (adapted from Finkel, 2011). 
 
1.3.3.6 Nrf2 signaling and its regulation by ROS 
A major regulator of antioxidant responses is the nuclear factor (erythroid 2)-like 2 
(Nrf2) (J. Zhang et al., 2016). Nrf2 belongs to the cap’n’collar (CNC)-b-zip family of 
transcription factors. Under non-stimulated conditions, Nrf2 associates with the 
Kelch-like ECH-associated protein-1 (Keap1) in the cytoplasm (Figure 16). Keap1 
interacts with the cullin-3 (Cul3)-containing E3-ubiquitin ligase complex, which results 
in ubiquitination and proteasomal degradation of Nrf2 (Villeneuve, Lau, & Zhang, 
2010). In conditions with elevated ROS levels, cysteine residues in Keap1 become 
oxidized, leading to the dissociation of Nrf2 from Keap1/Cul3 (D. D. Zhang & 
Hannink, 2003). Nrf2 becomes stabilized and translocates into the nucleus where it 
dimerizes with small Maf (musculoaponeurotic fibrosarcoma) proteins (Maf-F, Maf-G 
and Maf-K). The heterodimer binds to antioxidant response elements (AREs) and 
activates the transcription of target genes encoding for antioxidant proteins (Kensler, 
Wakabayashi, & Biswal, 2007). The BTB and CNC homolog 1 (Bach1) is a b-zip 
transcriptional repressor of the ARE (Ogawa et al., 2001). In the absence of cellular 
stress, Bach1 heterodimerizes with small Maf proteins and binds to the ARE, thereby 
repressing gene expression (Figure 16). Elevation of ROS levels cause the 
translocation of Bach1 to the cytoplasm and subsequent replacement by Nrf2, which 
ROS
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leads to ARE-dependent transcriptional activation (Ishikawa, Numazawa, & Yoshida, 
2005; Kaspar & Jaiswal, 2010).  
 
                                                 
Figure 16:  Redox regulation of the Nrf2 signaling pathway. Under non-stimulated conditions, Keap1 
associates with Nrf2 in the cytoplasm and targets it for proteasomal degradation following Cul3 
mediated polyubiquitination. ROS cause the oxidation of cysteine residues in Keap1, mediating the 
dissociation of Nrf2. Nrf2 translocates into the nucleus, dimerizes with small Maf proteins and binds to 
AREs of target genes. Bach1 represses ARE-dependent gene transcription under non-stimulated 
conditions. ROS lead to translocation of Bach1 from the ARE to the cytoplasm. Nrf2, nuclear factor 
(erythroid 2)-like 2; Keap1, Kelch-like ECH-associated protein-1; Cul3, cullin-2 E3-ubiquitin ligase; 
Bach1, BTB and CNC homolog 1; ARE, antioxidant response element (adapted from Ray, Huang, & 
Tsuji, 2012). 
 
1.3.3.7 NF-κB signaling and its regulation by ROS 
The mammalian NF-κB (nuclear factor kappa-light-chain-enhancer of activated B 
cells) proteins are of central importance in inflammation and immunity (Q. Li & 
Verma, 2002). These transcription factors consist of five related family members, 
which bind as homodimers or heterodimers to specific 10-bp κB sites of target genes 
(Morgan & Liu, 2011). NF-κB transcription factors are composed of a Rel homology 
(RHD) domain, which is needed for DNA binding and protein dimerization. RelA 
(p65), RelB and c-Rel have a C-terminal transcription activation domain (TAD) that is 
needed to positively regulate gene expression (Hayden & Ghosh, 2008). The two 
other family members are synthesized as larger p105 (NF-κB1) and p100 (NF-κB2) 
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precursor proteins. For DNA binding they need to be partially processed by the 
proteasome to the smaller p50 and p52 products, respectively (Hayden & Ghosh, 
2008). p50 and p52 do not activate transcription unless paired as a heterodimer with 
one of the Rel proteins, as they lack a TAD (Hayden & Ghosh, 2008). NF-κB activity 
is generally regulated by the inhibitory IκB (Inhibitor of κB) proteins, of which the 
typical IκBs are IκBα, IκBβ, and IκBε. IκB proteins bind to NF-κB proteins keeping 
them in the cytosol (Hayden & Ghosh, 2008). Upstream IκB kinases (IKKs) control 
the activity of the IκBs via phosphorylation (Hayden & Ghosh, 2008). The canonical 
and the non-canonical pathways are the two main signaling cascades which lead to 
the activation of NF-κB target genes (Hayden & Ghosh, 2008). The canonical NF-κB 
pathway is mainly activated by the stimulation of pro-inflammatory receptors (Figure 
17) (Q. Li & Verma, 2002). These receptors activate the IKK complex, which consists 
of the catalytic kinases IKKα and IKKβ, and the regulatory subunit IKKγ (NEMO) 
(Karin & Ben-Neriah, 2000). The p105 is constitutively processed into p50 (BEINKE 
& LEY, 2004). p50 is held inactive as a heterodimer with RelA (or c-Rel) by its 
interaction with the inhibitory IκB proteins. An activated IKK complex phosphorylates 
IκBα on serines 32 and 36 and targets it for ubiquitination and proteasomal 
degradation. The p50/RelA heterodimer is released to translocate into the nucleus 
where it can bind to κB sites and activate gene transcription (Hayden & Ghosh, 2008; 
Morgan & Liu, 2011; Vallabhapurapu & Karin, 2009). 
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Figure 17: Activation of the canonical NF-κB pathway. Upon stimuli-dependent receptor activation, 
the IKK complex becomes activated and phosphorylates IκBα. IκBα is targeted for proteasomal 
degradation, thereby releasing the p50/RelA heterodimer for nuclear translocation and activation of 
target gene transcription. IκBα, Inhibitor of κB; IKK, IκB kinase. 
 
ROS can interfere at different steps in the NF-κB signaling pathway and can both 
activate or inhibit NF-κB signaling, depending on the context and also cell type 
specific (Morgan & Liu, 2011). In cancer cells, NF-κB activation by ROS has been 
proposed to be mainly regulated via the IKK complexes. For example H2O2 has been 
shown to induce protein kinase D (PKD) phosphorylation, followed by IKKβ 
phosphorylation and NF-κB activation (Storz, Döppler, & Toker, 2004). Furthermore, 
various phosphatases are involved in the regulation of NF-κB signaling. For example, 
phosphorylation and activation of IKKβ has been shown to be reversed by protein 
phosphatase 2C beta (PP2Cβ), protein phosphatase 1A (PP1A) and protein 
phosphatase 1B (PP1B) (Prajapati, Verma, Yamamoto, Kwak, & Gaynor, 2004; Sun 
et al., 2009). Upon oxidation of cysteine residues, these phosphatases may become 
inactivated, causing a prolonged phosphorylation and activation of IKKβ (Brigelius-
Flohé & Flohé, 2011).  
Exogenous H2O2 and hypoxia/reoxygenation were shown to induce alternative 
phosphorylation of IκBα on Tyr42, leading to dissociation and activation of NF-κB 
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through an IKK-independent mechanism (Fan, Li, Ross, & Engelhardt, 2003; 
Schoonbroodt et al., 2000). In another cell model, H2O2 induced IKK-mediated 
phosphorylation of IκBα at Ser32 and Ser36, followed by NF-κB activation (Gloire et 
al., 2006), emphasizing that the H2O2 dependent NF-κB activation is cell type 
dependent. 
A protein with important roles in tumor progression, which has been shown to 
be regulated via the NF-κB signaling pathway, is tenascin-C (C. A. Pearson, 
Pearson, Shibahara, Hofsteenge, & Chiquet-Ehrismann, 1988; Tarassishin, Lim, 
Weatherly, Angeletti, & Lee, 2014). 
 
 
1.4 Tenascin-C 
Tenascin-C (TNC) belongs to the tenascin family of large extracellular matrix 
glycoproteins. Vertebrates express four tenascins termed tenascin-C, -R, -X and –W, 
with each tenascin having a specific expression pattern (Chiquet-Ehrismann & 
Chiquet, 2003). TNC is highly expressed during embryonic development, but almost 
absent during postnatal life, only some connective tissues like ligaments, tendons 
and smooth muscles are positive for TNC (F. S. Jones & Jones, 2000). Further, TNC 
re-expression occurs under conditions of tissue regeneration such as wound healing, 
inflammation and in the onset of tumorigenesis (Midwood & Orend, 2009; Tucker & 
Chiquet-Ehrismann, 2009).  
 
1.4.1 Tenascin-C and cancer 
TNC has been linked to cancer since its discovery in the mid-1980s (Bourdon, 
Wikstrand, Furthmayr, Matthews, & Bigner, 1983; Chiquet, 1984). TNC is 
overexpressed in many solid tumors (Chiquet-Ehrismann, Mackie, Pearson, & 
Sakakura, 1986; F. S. Jones & Jones, 2000) and high expression of TNC has been 
related to poor prognosis (Toshimichi Yoshida, Ishihara, Hirokawa, Kusakabe, & 
Sakakura, 1995) and local and distant recurrence in breast carcinomas (Jahkola et 
al., 1998b; Minn et al., 2005). TNC has repeatedly been shown to promote malignant 
tumor progression and lung metastasis (Midwood, Hussenet, Langlois, & Orend, 
2011; Orend, 2005; Oskarsson et al., 2011; Saupe et al., 2013). TNC expression has 
been linked to ER-negative and in general to invasive tumors of the breast (Dandachi 
et al., 2001; Ioachim et al., 2002; Shoji et al., 1992). The expression of TNC in early 
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breast cancer, has been suggested as predictor for an invasive behavior (Goepel, 
Buchmann, Schultka, & Koelbl, 2000; Jahkola, Toivonen, Nordling, Smitten, & 
Virtanen, 1998a). Strongest expression of TNC has been found at the invasive front 
of primary tumors (Orend & Chiquet-Ehrismann, 2006) and of metastases 
(Oskarsson et al., 2011). TNC is produced by myofibroblasts and angiogenic blood 
vessels in the cancer associated stroma (Chiquet-Ehrismann et al., 1986; Mackie et 
al., 1987) and by the cancer cell itself (Toshimichi Yoshida et al., 1997). 
 
1.4.2 Tenascin-C and its role in metastatic progression 
TNC has been implicated in various cellular functions which can promote metastasis, 
such as regulation of adhesion and migration, modulation of immune responses, 
promotion of angiogenesis and cancer cell-fitness (Lowy & Oskarsson, 2015). 
Depending on the occurrence of particular TNC splicing forms and on the overall 
ECM composition, TNC has been shown to have adhesive or anti-adhesive activities 
(Midwood & Orend, 2009). For example, TNC inhibits cell adhesion to fibronectin 
(Chiquet-Ehrismann, Kalla, Pearson, Beck, & Chiquet, 1988), whereby the shortest 
TNC isoform exhibits the strongest effect (Chiquet-Ehrismann et al., 1991). 
Furthermore, TNC has been shown to enhance the fitness of disseminated cancer 
cells and to promote the colonization of secondary organs in mouse models via 
modulation of Notch and Wnt signaling pathways (Oskarsson et al., 2011). TNC has 
also been proposed to have a pro-angiogenic role, as shown in experiments with 
TNC knockout mice where TNC was needed for neovascularization of the embryonic 
lung and heart (Van Obberghen-Schilling et al., 2011). Furthermore, TNC expression 
is induced upon vessel damage and is associated with vascular remodeling during 
dermal tissue repair (Betz, Nerlich, Tübel, Penning, & Eisenmenger, 1993; Fässler, 
Sasaki, Timpl, Chu, & Werner, 1996; Van Obberghen-Schilling et al., 2011). 
Additionally, TNC has been associated to the regulation of innate and adaptive 
immunity. TNC has been shown to activate toll-like receptor (TLR) 4, consequently 
stimulating the secretion of pro-inflammatory cytokines such as IL-6, IL-8 and TNF-α 
via NF-κB signaling (Midwood et al., 2009). Thereby, TNC plays an important role in 
the context of chronic immune diseases (Midwood et al., 2009), but whether TLR4 
activation by TNC is involved in tumor progression still needs to be examined. 
Furthermore, TNC has been shown to impact on the recruitment of macrophages 
(Talts, Wirl, Dictor, Muller, & Fässler, 1999), and to inhibit T-lymphocyte activation 
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(Puente Navazo, Valmori, & Ruegg, 2001), indicating that TNC may function as a 
regulator of inflammatory cells in tumors.  
 
1.4.3 Tenascin-C structure 
The human TNC gene is a large intron rich gene, located on chromosome 9 at locus 
9q32-34/9q33.1 (Gulcher, Alexakos, Le Beau, Lemons, & Stefansson, 1990; Rocchi, 
Archidiacono, Romeo, Saginati, & Zardi, 1991). TNC contains 29 exons of which 9 
can be alternatively spliced (Figure 18). The first exon is non-coding and contains the 
transcription start site. It is separated from exon 2 by a more than 20 kb long intron. 
Exon 2 contains the ATG start codon for translation initiation (Chiovaro, Chiquet-
Ehrismann, & Chiquet, 2015).  
 
                           
Figure 18: Schematic representation of the TNC gene. TSS1, transcription start site; e1, e2, e29, 
exons 1, 2, and 29; ATG, translation initiation start codon (Chiovaro et al., 2015). 
 
The human tenascin-C protein comprises four domains (Figure 19). The N-terminus 
contains the assembly domain (AD), which allows disulfide-linked homo-hexamer 
formation. This is followed by epidermal growth factor-like (EGF-L) repeats and a 
variable number of fibronectin type III-like (FNIII) repeats. The C-terminus contains a 
large fibrinogen-like globe (FG) (Chiquet-Ehrismann & Chiquet, 2003). The EGF-L 
repeats act as a ligand for the EGF-receptor, activating mitogen-activated protein 
kinase (MAPK) and phospholipase-C (PLC) signaling. The FNIII repeats interact with 
proteins such as integrins, aggrecan and perlecan, and bind to growth factors like 
platelet-derived growth factor (PDGF), transforming growth factor-β (TGFβ) and 
fibroblast growth factor (FGF) (Giblin & Midwood, 2014). The FG domain binds to 
integrins and activates Toll-like receptor-4 (TLR4) (Giblin & Midwood, 2014; Midwood 
et al., 2009).  
 
TNC
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Figure 19: Domain structure of full-length human TNC protein. AD, assembly domain; FG, fibrinogen 
globe; EGF, epidermal growth factor (Lowy & Oskarsson, 2015). 
 
1.4.4 Transcriptional regulation of tenascin-C 
Tenascin-C function is primarily regulated via the control of its expression at the 
transcriptional level. Many transcription factors have been shown to be involved in 
transcriptional regulation of TNC (Figure 20). TNC transcription may be induced or 
repressed in response to different stimuli, including inflammatory stimuli (C. A. 
Pearson et al., 1988; Sarközi et al., 2011; Tarassishin et al., 2014), reactive oxygen 
species (K. Yamamoto et al., 1999) and mechanical stress (K. Yamamoto et al., 
1999). 
 
 
Figure 20: Scheme of the TNC gene promoter/ enhancer with experimentally confirmed transcription 
factor binding sites, reported in human (dark blue) or mouse (green) TNC 3` flanking regions 
(Chiovaro et al., 2015). 
 
As TNC expression persists in the adult mainly in structures bearing high tensile 
stress, like ligaments, tendons and the smooth muscle walls of arteries, it is not 
surprising that TNC expression can be regulated by mechanical stimuli (Crameri et 
al., 2004; Mackie et al., 1992). External mechanical stimuli signal through integrins, 
which might cause the activation of ERK1/2, NF-κB or RhoA/ROCK (Sarasa-Renedo 
& Chiquet, 2005). In rat cardiomyocytes, TNC induction by cyclic mechanical strain 
was mediated by the release of ROS and the subsequent activation of NF-κB. An 
NF-κB binding site in the rat Tnc promoter was required for transcriptional Tnc 
activation and has been shown to be bound by the p50 subunit of NF-κB upon 
mechanical stimulation of the cardiomyocytes (K. Yamamoto et al., 1999). 
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Next to mechanical and oxidative stress, TNC has been shown to be inducible by 
pro-inflammatory cytokines like IL-1α (Maqbool et al., 2013) and IL-1β (Chevillard, 
Derjuga, Devost, Zingg, & Blank, 2007; Tarassishin et al., 2014) as well as by anti-
inflammatory cytokines like IL-4 (Gratchev, Kzhyshkowska, Utikal, & Goerdt, 2005) 
and IL-13 (Jinnin et al., 2006), in a cell-type specific manner. In human immune 
myeloid cells, toll-like receptor (TLR) ligands induced the expression of TNC via 
activation of NF-κB (Goh, Piccinini, Krausgruber, Udalova, & Midwood, 2010). 
Growth factors have also been shown to stimulate TNC gene expression. A direct 
role of TGF-β in promoting TNC expression has been observed in mammary 
epithelial cells (HC11) and mouse embryo fibroblasts (Scherberich et al., 2004). In 
astrocytes, the canonical SMAD-mediated TGF-β signaling pathway has been shown 
to be involved in TNC regulation (Wiese, Karus, & Faissner, 2012), and in fibroblasts 
it has been shown that SMADs regulate TNC expression via interaction with 
cofactors like SP1 and ETS1 in a complex with CBP/p300 (Jinnin et al., 2004).  
Transient overexpression of c-Jun induced tenascin-C expression in primary rat 
embryo fibroblasts and in a rat fibroblast cell line, involving the GCN4/AP1 and NFκB 
DNA-binding sequences in the Tnc promoter (Mettouchi et al., 1997). 
 
1.4.5 Post-transcriptional regulation of tenascin-C 
Tenascin-C is regulated post transcriptionally by alternative splicing. The TNC gene 
encodes for numerous different isoforms, generated through alternative splicing of 
exons within the fibronectin type III (FNIII) repeats (Figure 19) (Lowy & Oskarsson, 
2015). TNC isoforms range between 220-320 kDa, while most cancers express the 
larger isoforms of TNC. Splicing specificity can be context dependent and differs 
between tumor entities (Lowy & Oskarsson, 2015). In breast cancer, FNIII B and D 
domains and AD1 are expressed (Adams et al., 2002; Derr, Chiquet-Ehrismann, 
Gandour-Edwards, Spence, & Tucker, 1997). The regulation of TNC splicing and its 
relevance in metastasis are generally poorly understood.  
 
1.4.6 Assembly of tenascin-C into a fibrillar matrix 
Tenascin-C incorporation into the ECM is dependent on the presence of heparan 
sulfate proteoglycans (HSPGs) (Chung & Erickson, 1997), fibronectin, α5, αv and β1 
integrins (Ramos, Chen, Regezi, Zardi, & Pytela, 1998), and periostin (Kii et al., 
2010). The incorporation into a three-dimensional matrix likely changes the 
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conformation of TNC, exposing or masking specific domains and binding sites. 
Furthermore, the interaction with other matrix components may affect the availability 
of binding sites. Hence, the ECM function may differ depending on the conformation 
of tenascin-C and its interplay with other ECM components (Giblin & Midwood, 
2014).  
 
1.4.7 Proteolytic processing of tenascin-C 
Tenascin-C function is additionally regulated via proteolytic cleavage. TNC can be 
degraded in situations where a transient expression is required, such as in healing 
wounds, or proteolysis can release smaller fragments with different functions (Giblin 
& Midwood, 2014). TNC is susceptible to cleavage by matrix metalloproteinases 
(MMPs) and serine proteases (Imai, Kusakabe, Sakakura, Nakanishi, & Okada, 
1994; Siri et al., 1995), whereby different splicing forms show distinct sensitivity to 
specific proteases. For example, MMP2 and MMP3 cleave the large TNC isoform 
(Siri et al., 1995) exclusively at the FNIIIA3 domain (S. C. Bell, Pringle, Taylor, & 
Malak, 1999). MMP2 mediated cleavage generates a “cryptic binding site” (G. E. 
Davis, Bayless, Davis, & Meininger, 2000) within FNIII A2, exerting a pro-adhesive 
effect via α5β1 integrin activation (Saito et al., 2007; Tanaka et al., 2014).  
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2. Aims of the thesis 
 
The aims of the thesis were: 
 
1. To examine the relevance of chronic intermittent hypoxia for the modulation of 
gene expression in breast cancer cell lines. 
2. To elucidate the molecular mechanisms, which are involved in the modulation 
of gene expression upon chronic intermittent hypoxia. 
3. To analyze the effect of chronic intermittent hypoxia on breast cancer cell 
malignant properties. 
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ABSTRACT 
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. 
Treatment options are limited and the mechanisms underlying its aggressiveness are 
poorly understood. Intermittent hypoxia (IH) causes oxidative stress and is emerging 
as important regulator of tumor metastasis. Vessels in IBC tumors were shown to be 
immature, which is a primary cause of IH. We therefore investigated the relevance of 
IH for the modulation of gene expression in IBC cells in order to assess IH as 
potential regulator of IBC aggressiveness. Gene array analysis of IBC cells following 
chronic IH (45-60 days) demonstrated increased expression of pro-metastatic genes 
of the extracellular matrix, such as tenascin-C (TNC; an essential factor of the 
metastatic niche), and of inflammatory processes. Investigating the oxidative stress-
dependent regulation of TNC, we found a gradual sensitivity on mRNA and protein 
levels. Oxidative stress activated nuclear factor erythroid 2-related factor 2 (Nrf2), c-
Jun N-terminal kinase (JNK), c-Jun and nuclear factor κB (NF-κB), but TNC 
upregulation was only dependent on NF-κB activation. Pharmacological inhibition of 
inhibitor of NF-κB α (IκBα) phosphorylation and overexpression of IκBα prevented 
TNC induction, whereas the proinflammatory cytokine interleukin-1β (IL-1β) 
increased TNC expression. Analysis of the gene array results showed NF-κB binding 
sites for 64% of all upregulated genes, linking NF-κB and IH-dependent regulation of 
pro-metastatic gene expression in IBC cells. Our results provide a first link between 
intermittent hypoxia and pro-metastatic gene expression in IBC cells, revealing a 
putative novel mechanism for the high metastatic potential of IBC.  
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HIGHLIGHTS 
• Intermittent hypoxia (IH) increases pro-metastatic gene expression in IBC cells 
• ROS activates NF-κB, Nrf2 and c-Jun in IBC cells 
• IH-dependent gene regulation depends on NF-κB but no other redox signaling 
pathways 
• IH is proposed as an important regulator of IBC aggressiveness 
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INTRODUCTION 
Inflammatory breast cancer (IBC) is the most aggressive and most lethal form of 
primary breast cancer. While IBC is estimated to account for up to 5% of all breast 
cancer cases, it leads to approx. 8-10% of all breast cancer-related deaths [1-3]. IBC 
presents with a diffuse tumor formation and is highly metastatic with lymph node 
metastases being found in almost all and distant metastases in 30% of patients, 
respectively, at the time of diagnosis [2]. Treatment of IBC patients has proven to be 
challenging due to its rapid progression and aggressive nature [2, 4]. The 
mechanisms underlying the aggressiveness of IBC are still poorly understood, 
impeding the development of targeted therapy [2, 5]. In addition, the investigation of 
molecular signaling pathways leading to the development of the aggressive 
phenotype of IBC is difficult, because of a limited availability of tumor material and 
with only two primary tumor-derived cell lines existing [5, 6]. 
 Tumors frequently outgrow their blood oxygen supply, leading to insufficient 
oxygen levels (hypoxia) and subsequent induction of angiogenesis [7]. The induced 
tumor vessels are often not properly developed, leading to fluctuations of blood and 
hence oxygen supply [8]. Oxygen levels in solid tumors are therefore dynamic, with 
repeated cycles of hypoxia and reoxygenation, called chronic intermittent hypoxia 
(CIH) or cycling hypoxia [8]. CIH, although not directly assessed yet in IBC, likely 
also occurs in IBC tumors, because analysis of IBC tumor tissue showed hypoxia-
dependent gene expression (carbonic anhydrase IX (CA9) induction) in 50% of the 
tumors and overall a higher microvessel density than in other breast cancer forms [4, 
9, 10]. Moreover, approx. 90% of IBC tumor blood vessels are not fully developed 
[11]. Of note, CIH leads to enhanced tumor microvessel density, which could present 
a link to the increased microvessel density in IBC tumors [12]. In addition, CIH has 
been shown to be a stronger inducer of cancer metastases than continuous hypoxia 
[13, 14]. However, the role of CIH in IBC progression and aggressiveness is unclear. 
CIH is a major source of oxidative stress due to reactive oxygen species 
(ROS) generation [8, 15, 16]. Oxidative stress can affect gene expression through 
regulation of DNA methylation and transcription factor activity [15, 17, 18]. While the 
mechanism of oxidative stress-dependent regulation of DNA methylation is less 
clear, several transcription factors have been reported to be activated by oxidative 
stress, including nuclear factor erythroid 2-related factor 2 (Nrf2), hypoxia-inducible 
factor (HIF), activator protein-1 (AP-1) and nuclear factor κB (NF-κB) [15, 18, 19]. 
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Nrf2 is the main regulator of the cellular antioxidant response [20]. HIF is the master 
regulator of the transcriptional response to hypoxia but its activation by oxidative 
stress is still highly debated [8, 21-24]. AP-1 has been linked to the regulation of a 
wide range of cellular processes, including proliferation, migration and inflammation 
and has been described to play an important role in tumor cell proliferation in the 
context of oxidative stress [25, 26]. NF-κB is the master regulator of the cellular 
transcriptional response to inflammation [27, 28]. In cancer cells, NF-κB activity can 
increase the expression of genes that promote proliferation, invasiveness, metastasis 
and apoptosis [29, 30]. 
 The extracellular matrix (ECM) plays an important role in the development and 
progression of breast cancer [31]. For example, the matrix metalloproteinases 2 and 
9 (MMP2, MMP9) and a disintegrin and metalloproteinase 19 (ADAM19) are 
remodeling enzymes of the ECM and play a major part in the development of tumor 
metastasis and invasion [31, 32]. Tenascin-C (TNC), a large hexameric ECM 
glycoprotein, is highly expressed during development, almost absent during postnatal 
live, but re-expressed in case of injury and in the onset of tumorigenesis [33]. 
Increased expression of TNC has been related to poor prognosis, local and distant 
recurrence in breast carcinomas and metastasis formation [31, 34]. Of note, TNC has 
been shown to be an essential factor of the metastatic niche [31]. 
 In the current study, we investigated the impact of intermittent hypoxia and the 
resulting oxidative stress on transcriptional regulation in IBC cells. We provide 
evidence that CIH and oxidative stress are important regulators of pro-metastatic 
gene expression in IBC cells. Investigation of the underlying mechanism of 
upregulated TNC gene expression showed that it is dependent on NF-κΒ activation 
but not on DNA methylation, Nrf2, AP-1 and HIF. Furthermore, 64% of all CIH-
upregulated pro-metastatic genes can be regulated by NF-κΒ. These data provide a 
mechanistic link between intermittent hypoxia and pro-metastatic gene expression in 
IBC cells, contributing insights into the regulation of IBC aggressiveness. 
   Manuscript     
	
	
67	
MATERIAL AND METHODS 
Reagents 
Tert-butylhydroquinone (30 µM), dimethyl fumarate (40 µM), BAY11-7082 (12.5 µM, 
25 µM) and H2DCFDA (10 µM; Invitrogen) were dissolved in ethanol. L-Sulforaphane 
(10 µM) and SP600125 (10 µM, 20 µM) were dissolved in DMSO and N-acetyl-L-
cysteine (3 mM, 20 mM) was dissolved in H2O. IL-1β was dissolved in 0.1% BSA in 
PBS. 
 
Cell culture and treatments 
The human triple-negative breast cancer cell line SUM149PT was kindly provided by 
Rachael Natrajan (London, UK) and was used for all subsequent cell culture 
experiments. SUM149PT cells were cultured in equal parts of high-glucose DMEM 
(Sigma-Aldrich) and Ham's F-12 Nutrient Mixture (Gibco, Thermo Fischer Scientific, 
Waltham, MA, USA), supplemented with 5% heat-inactivated fetal bovine serum 
(FBS), 1 µg/ml hydrocortisone (Sigma-Aldrich), 5 µg/ml human insulin (Sigma-
Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Reagents 
were diluted to the required concentration in DMEM/F-12 medium without FBS and 
supplements. SUM149PT cells were seeded at 70-80% confluency. BAY11-7082, 
SP600125 and N-acetyl-L-cysteine were added to the cells 1 h before addition of 
tBHQ. Hypoxic experiments were carried out in a humidified atmosphere containing 
0.2% O2 and 5% CO2 in a gas-controlled glove box (Invivo2 400, Baker Ruskinn, 
Bridgend, UK) as previously described [35]. 
 
mRNA analysis and data deposition 
The RNeasy mini kit (Qiagen, Hilden, Germany) was used for total RNA extraction for 
the Affymetrix gene array analysis according to manufacturer’s protocol. Affymetrix 
Human Gene 2.1 ST strip arrays were used to analyze transcript levels of one 
biological replicate of untreated cells and of cells cultured for 45 days in CIH. The 
data were deposited in Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through the ID GSE81416. For 
validation of the Affymetrix gene array results three biological replicates of untreated 
cells and cells that were cultured for 45 days in normoxia or CIH conditions were 
analyzed by RT-qPCR as previously described [36]. The relative mRNA expression 
was calculated using the ΔΔCt formula. U6 snRNA served as control gene and values 
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were normalized to the average values of normoxic controls. For all further 
experiments, total cellular RNA was extracted as previously described [37]. Primer 
sequences were listed in Supplementary Table S3. mRNA copy numbers were 
calculated by comparison with serial dilutions of a calibrated standard, calculated 
relative to U6 snRNA levels and normalized to starting time point if not otherwise 
indicated. 
 
Bioinformatic analysis of Affymetrix gene expression array 
For the analysis of the Affymetrix gene array results, protein coding genes, as listed 
in the National Center for Biotechnology Information (NCBI) Reference Sequence 
(RefSeq) database, with ≥ 4-fold increased transcript levels were used for 
bioinformatic analyses with MetaCore (https://portal.genego.com/) from Thomson 
Reuters. Enrichment analysis according to standard settings of the software was 
performed to rank the most relevant cellular processes. p values were calculated as 
–log10. To analyze literature-based transcriptional regulations the “build network” 
option with the algorithm for “transcription regulation” was applied. In order to link 
single genes to the matrisome, analysis was performed via the matrisome project for 
each upregulated gene (http://matrisomeproject.mit.edu/proteins/) [38]. For detection 
of conserved transcription factor binding sites (TFBS), the web-based software 
oPOSSUM version 3 (http://opossum.cisreg.ca/oPOSSUM3/) was used [39-41]. The 
matrices of TFBS profiles included in oPOSSUM-3 were obtained from the 2010 
release of the JASPAR database (http://jaspar.genereg.net). For in silico analysis of 
expression data the R2 database (http://hgserver1.amc.nl/cgi-bin/r2/main.cgi) was 
searched across datasets and 2D gene overview options were used for correlations 
between TNC and p105 in Affymetrix HG-U133plus2.0-based expression profiles 
normalized using MAS5.0. The following GEO IDs were employed for our analyses: 
GSE76124, GSE21653, GSE3494, GSE25066. For detection of TFBS’ in the TNC 
promoter, the UCSC genome browser (http://genome.ucsc.edu/) was searched with 
the genome assembly released in February 2009 [42]. Further, the Swissregulon 
(http://swissregulon.unibas.ch/fcgi/sr) and the JASPAR databases [43] were 
searched. 
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Protein detection and quantification 
Proteins were extracted from cells using 0.4 M NaCl, 1% Nonidet P-40, 10 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 
mM sodium-orthovanadate and protease inhibitor cocktail (P2714, Sigma-Aldrich). 
Equal amounts of protein were separated by SDS-PAGE, transferred to nitrocellulose 
membranes and detected with antibodies against HIF-1α (BD Transduction 
Laboratories, Allschwil, Switzerland), β-actin (Sigma-Aldrich), SMC1 (Abcam, 
Cambridge, UK), tenascin-C (H-300, Santa Cruz Biotechnology, Dallas, TX, USA), 
Nrf2 (H-300, Santa Cruz Biotechnology), α-tubulin (Sigma-Aldrich), c-Jun (Cell 
Signaling Technologies, Danvers, MA, USA), phospho-c-Jun(Ser63) (Cell Signaling 
Technologies), phospho-c-Jun(Ser73) (Cell Signaling Technologies), IκBα (Cell 
Signaling Technologies), phospho-IκBα (Cell Signaling Technologies), and Nrf3 [44]. 
Quantification of immunoblotting signals were performed by ImageJ 1.48v 
(http://imagej.nih.gov/ij) or as previously described [35]. Values were normalized to β-
actin loading control and to the average values of normoxic controls if not otherwise 
indicated. 
 
siRNAs and plasmids 
For siRNA experiments, cells were seeded to reach 60% confluency on the day of 
transfection. Nrf2 siRNA (ON-TARGET plus Human NFE2L2 siRNA, SMART pool), 
Nrf3 siRNA (ON-TARGET plus Human NFE2L3 siRNA, SMART pool), c-Jun siRNA 
(ON-TARGET plus Human JUN siRNA, SMART pool) and non-target siRNA (ON-
TARGET plus Non-targeting Pool) were purchased from Dharmacon (GE Healthcare, 
Lafayette, CO, USA) and transfected using Lipofectamine 2000 (Invitrogen) and Opti-
MEM (GIBCO) according to manufacturers' protocols. For plasmid transfections, cells 
were seeded to reach 70% confluency on the day of transfection. NC16 pcDNA3.1 
FLAG Nrf2 was a gift from Randall Moon (Addgene plasmid # 36971) [45], pCMV4-3 
HA/IκBα was a gift from Warner Greene (Addgene plasmid # 21985) [46] and 
pcDNA3.1-hNFE2L3 has previously been published [44]. Following 24 h of 
transfection, treatments were performed. 
 
H2DCFDA assay 
SUM149PT cells were seeded in 96-well plates at 80% confluency and incubated 
with 10 µM 2'7'-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen) for 30 
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min in the dark. Subsequently, specific treatments were performed and fluorescence 
was measured using a 96-well fluorescence photometer (Infinite 200Pro, Tecan, 
Männedorf, Switzerland). For combined treatments with tert-butylhydroquinone and 
N-acetyl-L-cysteine, cells were pretreated for 1 h with N-acetyl-L-cysteine. Results 
were calculated as increase in fluorescence per well ((Ftx – Ft0) / Ft0*100), where 
Ftx = fluorescence at a certain time point and Ft0 = fluorescence at 0 min [47]. For 
hypoxia-reoxygenation experiments, 96-well plates were incubated for 24 h in 0.2% 
oxygen. Cells were incubated with H2DCFDA inside the hypoxia workstation and 
fluorescence measurements were performed immediately thereafter. 
 
DNA methylation analyses 
Quantification of CpG density in the genomic sequence of TNC was carried out using 
MethPrimer Software (http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi) 
[48]. Genomic DNA was treated with bisulfite prior to methylation-specific PCR (MSP) 
or bisulfite sequencing PCR (BSP) using the EZ-DNA methylation-Gold kit (Zymo 
Research Corp, Irvine, CA, USA) as per manufacturer's description. MSP was 
performed on 5 ng bisulfite-treated DNA using the outlined primers ( Supplementary 
Table S3), targeting CpG island in the TNC promoter region [49]. BSP was 
performed using M13-tailed primers (primers designed: MethPrimer software), 
targeting the CpG island in the promoter region or the first untranslated exon, 
respectively, of the TNC gene. 
 
Statistical analyses 
If not otherwise indicated, results are presented as mean values ± standard error of 
the mean (SEM) of at least three independent experiments. Statistical analyses were 
performed using Student's t-test and one-way ANOVA or two-way ANOVA where 
appropriate. P-values <0.05 were considered statistically significant. 
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RESULTS 
Chronic intermittent hypoxia increases pro-metastatic gene expression in 
inflammatory breast cancer cells. 
In order to investigate the impact of CIH on IBC, the primary tumor-derived IBC cell 
line SUM149PT was cultured for 45 days in CIH conditions (15 cycles of 
hypoxia/reoxygenation; Fig. 1A) and gene expression was assessed by whole 
genome microarray hybridization. Using a four-fold difference relative to control as 
threshold for relevant gene regulation, 37 genes were identified to be upregulated 
and 51 genes to be downregulated in response to CIH. Analysis of associations of 
the upregulated genes with cellular processes via MetaCore 
(https://portal.genego.com/) showed that these genes are primarily involved in the 
regulation of the ECM (Fig. 1B). 13 out of the 37 upregulated genes were linked to 
the “matrisome”, which is composed of ECM and ECM-associated proteins (Fig. 1B, 
Supplementary Table S1) [38]. A second relevant process associated with CIH-
upregulated gene expression was inflammation (Fig. 1B). 
The CIH experiment was repeated to validate the expression levels of 10 out 
of the 37 upregulated genes. TNC, MMP2, MMP9 and ADAM19 were chosen 
because these proteins are important components and remodeling enzymes of the 
ECM, and since they have previously been shown to play a major role in tumor 
invasion and metastasis [31, 32]. Triggering receptor expressed on myeloid cells 
(TREM1), interleukin-1α (IL1A) and cyclooxygenase-2 (COX-2; gene name: PTGS2, 
prostaglandin G/H synthase 2) have been linked before to inflammatory processes 
and COX-2 has been associated with a more aggressive breast cancer phenotype 
[2]. nuclear factor erythroid 2-related factor 3 (Nrf3, gene name: NFE2L3) is a 
homolog of the transcription factor Nrf2 and might be part of the oxidative stress 
response [50]. Src homology 2 domain containing family member 4 (SHC4) plays a 
critical role in migration of metastatic melanomas and potentially in the response to 
oxidative stress-induced DNA damage; and a SNP in X-ray repair complementing 
defective repair in Chinese hamster cells 2 (XRCC2), which is involved in 
homologous recombination DNA repair, was linked to spontaneous breast cancer 
development [51-53]. We analyzed the expression pattern of these genes in 
response to hypoxia, reoxygenation (both part of cycle 1 of the CIH experiment; Fig. 
1A) and CIH (15-20 cycles; Fig. 1A). All genes except MMP9 demonstrated a 
significant upregulation following CIH (Fig. 2A). But also MMP9 showed an 
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upregulation in response to CIH in all three independent experiments, only with a 
higher degree of variability. To analyze the expression patterns further, we directly 
compared the observed induction factors of the different treatments to each other 
and identified three differentially regulated groups (Fig. 2B). Group I showed only 
upregulated gene expression in response to CIH, while group II genes were already 
increased in response to a single reoxygenation stimulus (Fig. 2B). Group III was 
upregulated by all three treatments (Fig. 2B). These findings indicate that some of 
these genes are only sensitive to a higher oxidative stress such as CIH (group I), 
while others are already upregulated by a single reoxygenation event (group II). In 
group III, we most likely observed overlapping regulation between hypoxia and the 
oxidative stress response. Of note, no increase in prototypical HIF target genes (e.g. 
CA9 or glycolytic enzymes) was observed in the gene array following CIH, indicating 
that HIF-dependent gene expression was not present in our CIH conditions at the 
time of analysis. In order to determine if CIH also led to increased protein levels, we 
determined TNC protein expression following the three different treatments. TNC 
protein expression followed the same pattern as its mRNA, with no upregulation in 
response to hypoxia or a single reoxygenation event but with a significant increase 
following 15 and 20 cycles of CIH (Fig. 2C, D). 
Overall, these results demonstrate that CIH increases pro-metastatic gene 
expression in IBC cells. In addition, we identified three distinct groups of regulated 
genes, indicating a differential sensitivity to oxidative stress and hypoxia among the 
investigated genes. The observed changes on mRNA levels translated into protein 
expression, indicating functional relevance. 
 
Tenascin-C expression demonstrates a gradual sensitivity to increasing 
oxidative stress levels 
We next investigated the underlying mechanism of the CIH-dependent increase in 
pro-metastatic gene expression. We focused on TNC expression because its mRNA 
and protein levels were specifically upregulated in response to CIH and not by 
hypoxia, demonstrating that its regulation depends on repeated reoxygenation events 
(Fig. 2). Furthermore, TNC has been linked to breast cancer development, it plays a 
major role in tumor progression and metastasis, and it has been shown to be an 
essential factor of the metastatic niche [31]. Because CIH is a well-established 
oxidative stress inducer and likely leads to a more severe oxidative stress than a 
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single reoxygenation event [8, 15, 54], we aimed to investigate the effect of 
increasing oxidative stress conditions on TNC-dependent gene expression. First, we 
compared the potential of different stimuli, a single hypoxia/reoxygenation phase, 
hydrogen peroxide (H2O2; Sigma-Aldrich, St Louis, MO, USA) and tert-
butylhydroquinone (tBHQ; Sigma-Aldrich), to induce oxidative stress in SUM149PT 
cells using the H2DCFDA assay (Invitrogen, Thermo Fischer Scientific, Waltham, MA, 
USA) (Fig. 3A-C). Hypoxia/reoxygenation led to a short but significant increase in 
DCF fluorescence at early time points (0.5 h) (Fig. 3A), while 100 µM H2O2 led to a 
prolonged, plateauing increase in fluorescence over 4 h (Fig. 3B). 30 µM tBHQ 
induced a steady increase in fluorescence over 4 h and the observed signal was up 
to 4-fold higher than with single hypoxia/reoxygenation or H2O2 (Fig. 3A-C). This 
established the following order of ROS induction by these treatments: tBHQ (30 µM) 
> H2O2 (100 µM) > single reoxygenation. 
Next, we investigated the impact of the different ROS sources on TNC mRNA 
and protein expression. Hypoxia/reoxygenation led to a significant but short and 
transient increase in TNC mRNA levels at 2 and 4 h (Fig. 3D), while H2O2 
significantly induced TNC mRNA at 4-8 h (Fig. 3E) and tBHQ at 9 h and 24 h (Fig. 
3F), with 5 to 9-fold higher TNC mRNA levels following tBHQ treatment compared to 
the other treatments (Fig. 3D-F). On the protein level, hypoxia/reoxygenation neither 
induced TNC (Fig. 3G, J) nor activated the positive control for oxidative stress, the 
redox-sensitive transcription factor Nrf2 (data not shown). CA9 mRNA levels and 
HIF-1α protein levels were used as positive controls for hypoxia (Fig. 3G, 
Supplementary Fig. S1A). In turn, H2O2 increased TNC protein levels significantly 
after 6 h (Fig. 3H, K). Nrf2 protein was stabilized and its target gene heme 
oxygenase 1 (HO-1) was elevated in response to H2O2 treatment (Fig. 3H, 
Supplementary Fig. S1B). tBHQ treatment led to a strongly increased protein 
expression at 9 h and 24 h (Fig. 3I, L). Nrf2 protein levels and HO-1 mRNA were also 
elevated by tBHQ (Fig. 3I, Supplementary Fig. S1C). Of note, the observed 
differences of activated Nrf2 protein levels between the treatments are in agreement 
with the differences of ROS measured by the H2DCFDA assay (tBHQ > H2O2 > 
single reoxygenation), further supporting a differential ROS induction between the 
treatments (Fig. 3A-C, G-I). 
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 Overall, TNC expression shows a gradual sensitivity to ROS levels in 
inflammatory breast cancer cells, indicating that CIH increases TNC expression 
through increasing oxidative stress. 
 
Antioxidant treatment prevents oxidative stress-mediated TNC induction 
We next sought to determine if the observed TNC induction was directly dependent 
on ROS. SUM149PT cells were pre-treated with the antioxidant N-acetyl-L-cysteine 
(NAC; Sigma-Aldrich) for 1 h followed by the addition of tBHQ. NAC prevented tBHQ-
mediated ROS production (Fig. 4A) as well as tBHQ-mediated upregulation of TNC 
protein levels (Fig. 4B and C). These results demonstrate that regulation of TNC 
expression is directly linked to oxidative stress and can be prevented by antioxidant 
treatment. 
 
Chronic intermittent hypoxia-dependent TNC induction is not regulated by 
changes in DNA methylation 
DNA methylation is frequently involved in chronic changes of gene expression and 
can be regulated by oxidative stress [17]. Therefore, we investigated a potential 
impact of CIH on DNA methylation as molecular mechanism for the regulation of 
TNC expression. First, the regions upstream and downstream of the transcriptional 
start site of the TNC gene were analyzed with the MethPrimer software 
(http://www.urogene.org/methprimer/) [48]. This identified a CpG-rich region in the 
TNC promoter and in the first untranslated exon of TNC (Fig. 5A). Analysis by 
methylation-specific PCR (MSP) showed no difference in methylation of the TNC 
promoter following CIH (Fig. 5B). Analysis by bisulfite sequencing PCR (BSP) 
detected also no change in methylation after CIH, neither in the TNC promoter nor in 
the first exon of TNC (data not shown). Hence, the observed elevated TNC 
expression upon CIH is not caused by changes in DNA methylation. 
 
Oxidative stress-dependent TNC induction is independent of Nrf2 and Nrf3 
A main transcription factor activated by oxidative stress is Nrf2 [20] and Nrf2 protein 
was stabilized and Nrf2-dependent target genes were increased in SUM149PT cells 
following H2O2 and tBHQ treatment (Fig. 3H, I, Supplementary Fig. S1B, C). In 
addition, in response to CIH we observed elevated Nrf3 mRNA levels (Fig. 2A). Nrf3 
belongs to the same transcription factor family as Nrf2 (Cap’n’Collar family) and has 
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also been linked to the cellular antioxidant response [50]. Furthermore, the TNC 
promoter can be regulated by BACH1, a transcriptional suppressor binding 
antioxidant response elements (ARE) (Fig. 6A) [55]. Following oxidative stress, 
BACH1 does not suppress ARE-dependent transcription anymore [55], so that for 
example Nrf2 or Nrf3 can bind to regulate gene expression (Fig. 6A). Therefore, we 
transiently knocked down Nrf2 and/or Nrf3 in SUM149PT cells, followed by tBHQ 
treatment. No significant difference in tBHQ-dependent TNC induction was detected 
with single or combined Nrf2 and Nrf3 knockdown (Fig. 6B-D), while HO-1 induction, 
a known direct Nrf2 target gene, was significantly affected (Fig. 6B-D) [20]. Single 
and combined knockdown or overexpression of Nrf2 and Nrf3 showed also no major 
effect on basal TNC gene expression (Supplementary Fig. S2). In addition, the effect 
of two chemical Nrf2 activators on TNC expression was tested, L-sulforaphane (SFN; 
Sigma-Aldrich) and dimethyl fumarate (DMF; Sigma-Aldrich). SFN and DMF mediate 
stabilization and nuclear translocation of Nrf2 by modulating the inhibitory protein of 
Nrf2, kelch-like ECH-associated protein 1 (Keap1) [56, 57]. SUM149PT cells were 
treated with 10 µM SFN and samples were collected for up to 24 h. No change in 
TNC mRNA expression was detected, while the induction of HO-1 6 h after treatment 
demonstrated efficient Nrf2 activation (Fig. 6E). Treatment with 40 µM DMF caused 
only a slight elevation in TNC mRNA levels after 24 h, but showed a significant HO-1 
induction from 3 h to 9 h (Fig. 6F). Increased TNC mRNA levels through DMF 
stimulation correlated with increased ROS levels while SFN caused no significant 
ROS production and no elevated TNC mRNA levels (Supplementary Fig. S3). Of 
note, the increase in ROS following DMF treatment was much lower than the ROS 
levels measured after H2O2 treatment and negligible compared to the ROS 
production caused by tBHQ (Fig. 3B, C, Supplementary Fig. S3). 
Overall, these results demonstrate that oxidative stress-dependent TNC 
induction is independent of Nrf2 and Nrf3. 
 
Oxidative stress-dependent TNC induction is independent of JNK and c-Jun 
activity. 
Another transcription factor activated by oxidative stress and IH is AP-1, which is 
regulated by mitogen-activated protein kinase (MAPK) signaling [15, 18, 25]. AP-1 is 
a dimeric protein that can be composed of several different subunits of which the 
major protein subfamilies are Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, 
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Fra-2) [25]. The TNC promoter contains ChIP-based binding sites for AP-1 subunits 
such as c-Jun (Fig. 6A). tBHQ increased over a time course of 24 h c-Jun 
phosphorylation on serine 63 and 73, which enhances c-Jun transcriptional activity 
(Fig. 7A) [25]. In addition, total c-Jun protein levels were increased (Fig. 7A). c-Jun 
has been reported to be phosphorylated on serine 63 and 73 by the MAPK c-Jun N-
terminal kinase (JNK) [25]. Therefore, we next investigated if tBHQ-dependent c-Jun 
phosphorylation could be prevented by the JNK inhibitor SP600125 (Selleck, 
Houston, TX, USA). One hour pre-treatment with SP600125 blocked tBHQ-
dependent c-Jun phosphorylation (Fig. 7B), indicating that tBHQ activates the MAPK 
signaling cascade at the level of or upstream of JNK. However, the JNK inhibitor did 
not prevent tBHQ-mediated TNC induction (Fig. 7C, D). Furthermore, siRNA-
mediated knockdown of c-Jun did also not significantly affect tBHQ-dependent TNC 
induction (Fig. 7E, F). These results show that oxidative stress activates MAPK 
signaling and c-Jun in IBC cells but the oxidative stress-dependent increase of TNC 
is independent of this mechanism. 
 
Oxidative stress-dependent TNC induction is mediated by NF-κB. 
A further transcription factor activated by oxidative stress is NF-κB, which also has a 
putative binding site in the TNC promoter (Fig. 6A). Hence, we next tested if tBHQ 
can activate NF-κB in IBC cells and treated SUM149PT cells with tBHQ over a 24 h 
time course. This led to a time-dependent decrease of inhibitor of NF-κB α (IκBα) 
protein levels (Fig. 8A), demonstrating activation of the NF-κB signaling pathway. 
Pre-treatment with BAY11-7082 (Selleck), which prevents phosphorylation and 
subsequent degradation of IκBα [58], blocked the tBHQ-dependent decrease of IκBα 
(Fig. 8B), indicating that tBHQ-mediated oxidative stress activates the NF-κB 
signaling pathway at the level of or upstream of IκBα phosphorylation. Inhibitor 
treatment 1 h prior to the tBHQ stimulus abrogated the increase in TNC expression 
(Fig. 8C, D), indicating that NF-κB regulates oxidative stress-mediated TNC 
induction. Overexpression of IκBα also prevented oxidative stress-dependent 
induction of TNC, confirming its regulation by the NF-κB signaling pathway (Fig. 8E). 
Treatment with the major pro-inflammatory cytokine IL-1β (R&D systems, 
Minneapolis, MN, USA), one of the best-characterized NF-κB activating stimuli [58, 
59], showed a decrease of IκBα levels at 30 min and a strong increase in TNC 
   Manuscript     
	
	
77	
protein levels from 3-24 h (Fig. 8F). Analysis of breast cancer transcriptomic datasets 
revealed a significant, positive correlation between TNC and nuclear factor κB p105 
subunit (p105) levels (Supplementary Fig. S4). Together with the previous results, 
this demonstrates that oxidative stress-induced TNC expression is regulated by NF-
κB. Interestingly, when we investigated our CIH gene array results for transcription 
factor binding sites and known regulation by transcription factors using oPOSSUM 
and MetaCore (http://opossum.cisreg.ca/oPOSSUM3/ and 
https://portal.genego.com/), 64% of all upregulated genes showed a possible 
regulation by NF-κB (Fig. 8G, Supplementary Table S2). Analysis for binding sites for 
AP-1 and Nrf2 revealed a putative regulation of 33% by Nrf2 and of 83% by AP-1 
with 30.6% of these genes showing overlapping regulation by Nrf2, AP-1 and NF-κB 
(Supplementary Fig. S5). 
 Overall, our results demonstrate that oxidative stress-dependent TNC increase is 
specifically regulated by NF-κB and that this transcription factor might also play an 
important role in the upregulation of other pro-metastatic genes in IBC cells in 
response to CIH. 
  
   Manuscript     
	
	
78	
DISCUSSION 
Inflammatory breast cancer is the primary breast cancer form with the highest 
aggressiveness [2, 3, 60]. The underlying mechanisms are still unclear but are 
urgently needed to be deciphered in order to develop novel treatment options [5]. 
CIH is a common feature of tumors, but it is only beginning to be appreciated as an 
important regulator of cancer progression and metastases. It occurs when cancer 
cells outgrow the area of sufficient oxygen delivery and subsequent hypoxia-induced 
tumor angiogenesis leads to vessels with abnormal structures [8]. Such changes 
have also been demonstrated for IBC tumors [7, 11]. CIH is a well-established source 
for oxidative stress, which can severely impact on gene expression, leading to 
increased cancer aggressiveness [16]. However, the relevance of CIH for IBC 
progression and metastases formation is unclear. In this study, we provide insights 
into the regulation of pro-metastatic gene expression through IH and oxidative stress 
in IBC cells, which appears to be mediated mainly by NF-κB (Fig. 9). 
In our investigations, we identified that CIH leads to increased expression of 
ECM proteins in IBC cells, such as TNC, MMP2, MMP9 and ADAM19, and of 
proteins involved in inflammatory processes, such as COX-2. TNC, MMP2, MMP9 
and COX-2 have previously been shown to highly promote breast cancer 
metastases, and to be significantly stronger expressed in IBC tumors in comparison 
to non-IBC breast cancer tumors [2, 31, 60, 61]. Tumor inflammation has also been 
associated with cancer progression and metastasis formation and COX-2 was 
identified as a major component of the IBC molecular signature and suggested for 
targeted therapy for IBC [2, 62]. Overall, these data demonstrate that CIH leads to 
the upregulation of pro-metastatic gene expression in IBC cells, which likely 
contributes to the aggressive phenotype of IBC. 
The transcriptional regulation of the TNC gene is complex and several 
different stimuli and transcription factors are involved [63]. TNC has previously been 
shown to be regulated by AP-1, NF-κB and Nrf2 [63-65], and although we observed a 
ROS-dependent activation of Nrf2, JNK and c-Jun in IBC cells, these factors did not 
regulate TNC. In our gene array, 33% of CIH-upregulated genes were identified to 
carry a putative Nrf2 binding sequence, but we did not observe any prototypical Nrf2 
target gene, such as HO-1 or other genes of the cellular antioxidants defense system 
[20]. Therefore, it seems unlikely that Nrf2 plays a major role in the here observed 
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gene expression and no clear link between Nrf2 activity and IBC has been reported 
so far. 
The relevance of MAPK signaling and AP-1 activation in IBC is unclear, but 
overexpression of AP-1 subunits such as c-Jun and MAPK hyperactivation have 
been suggested [66, 67]. While ROS-dependent TNC induction was independent of 
c-Jun, 83% of the CIH-upregulated genes could potentially be regulated by AP-1. 
Therefore, a contribution of AP-1 to CIH-dependent gene regulation in IBC cells 
cannot be excluded but would need further investigations to determine its relevance. 
We also observed oxidative stress-dependent activation of the NF-κB 
signaling cascade at the level of or upstream of IκBα and TNC was regulated by 
activation of the NF-κB pathway. TNC has previously been suggested as a putative 
NF-κB target gene in IBC [60, 68], but although TNC is regulated by this transcription 
factor in other cell types, to our knowledge an NF-κB -dependent TNC regulation had 
not been shown in IBC cells before. 
The term “inflammatory breast cancer” could suggest an inflammation-driven 
cancer, but it originated from the clinical appearance of patients [4, 69]. The role of 
inflammation in IBC aggressiveness is only beginning to be unraveled. Several 
studies indicated NF-κB to be constitutively activated in IBC and to be a major 
contributor to IBC-specific gene expression and tumorigenesis [2, 60, 67, 70]. As 
mechanisms for increased NF-κB activity, infection with human cytomegalovirus 
(HCMV), loss of estrogen receptor (ER) and differential cytokine expression has 
been suggested [2]. In our study, we found that oxidative stress activates NF-κB in 
IBC cells and that 64% of all CIH-upregulated genes can potentially be regulated or 
have been shown to be regulated by NF-κB, such as COX-2 [71]. TNC gene 
induction by oxidative stress was directly linked to NF-κB activation and increased 
TNC expression was associated with increased p105 expression in breast cancer 
tissue. Overall, these results demonstrate the importance of NF-κB in pro-metastatic 
gene regulation in IBC cells in response to intermittent hypoxia. Interestingly, TNC 
can activate toll-like receptor 4, which in turn activates NF-κB, leading to a regulatory 
loop [68, 72]. Furthermore, IH and inflammation can form a vicious circle in vivo, 
amplifying each other [73]. We therefore hypothesize that IH and oxidative stress 
play an important role in the constitutive activation of NF-κB in IBC, which is 
facilitated through increased TNC expression. 
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 In summary, CIH is a possible novel modulator of IBC aggressiveness, increasing 
pro-metastatic gene expression through activation of NF-κB and maybe other 
transcription factors. Both CIH and NF-κB should be further investigated as potential 
targets for therapy of inflammatory breast cancer. The impact of CIH should be 
considered in future studies of IBC tumor material, as CIH affects gene and protein 
expression and could lead to differences in expression levels between different 
biopsy sites. Taking into consideration the crosstalk between the tumor 
microenvironment and the tumor, such as between intermittent hypoxia and IBC 
cells, might allow us to develop novel approaches for IBC treatment. 
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FIGURE 1 
 
             
 
Fig. 1: Genes regulated by chronic intermittent hypoxia (CIH) in inflammatory 
breast cancer cells. (A) Experimental scheme of the CIH exposure regime, 
indicating the duration of exposure to hypoxia and normoxia, and the time points of 
sample collection. (B) Enrichment analysis of upregulated genes using MetaCore 
software to rank the most relevant cellular processes. 
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Figure 2 
 
      
 
Fig. 2: Gene array validation reveals three distinct groups of genes regulated 
by CIH. (A) Validation of gene array results for selected candidate genes in 
SUM149PT cells by RT-qPCR. (B) Heatmap showing the mRNA induction factors 
depicted in (A) following hypoxia, reoxygenation or CIH. (C) Immunoblot analysis of 
TNC protein levels in response to hypoxia, reoxygenation or CIH. (D) Quantification 
of TNC protein levels following hypoxia, reoxygenation or CIH. *, p<0.05; **, p<0.01; 
***, p<0.001 (Student’s t-test). 
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Figure 3 
 
  
 
Fig. 3: Regulation of TNC gene expression by oxidative stress. H2DCFDA 
assays to quantify the generation of intracellular ROS levels by (A) reoxygenation 
(following 24 h 0.2% O2), (B) 100 µM H2O2 or (C) 30 µM tBHQ over 4 h. RT-qPCR 
analysis of TNC mRNA induction in response to (D) reoxygenation (following 24 h 
0.2% O2), (E) 100 µM H2O2 or (F) 30 µM tBHQ over the indicated time course. TNC 
immunoblot analysis in response to (G) reoxygenation (following 24 h 0.2% O2), (H) 
100 µM H2O2 or (I) 30 µM tBHQ over the indicated time course. Quantification of 
TNC protein levels in response to (J) reoxygenation (following 24 h 0.2% O2), (K) 
100 µM H2O2 or (L) 30 µM tBHQ over the indicated time course. *, p<0.05; **, 
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p<0.01; ***, p<0.001 (one-way ANOVA followed by Tukey test for (D, J); two-way 
ANOVA followed by Bonferroni posttest for all other statistical analyses). 
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Figure 4 
 
      
 
Fig. 4: Effects of antioxidants on tBHQ-mediated TNC induction. (A) H2DCFDA 
analysis of tBHQ treatment (30 µM) alone or following 1 h pre-treatment with 3 mM 
NAC. (B) Analysis of TNC protein levels in SUM149PT cells in response to 30 µM 
tBHQ alone or following 1 h pre-treatment with 3 mM or 20 mM NAC. (C) 
Quantification of relative TNC protein levels. Values were normalized to β-actin 
loading control and to the starting time point. n.s., not significant; **, p<0.01; ***, 
p<0.001 (Two-way ANOVA followed by Bonferroni posttest was applied for 
comparison of tBHQ treatment alone with the combinatorial treatment of tBHQ and 
NAC in (A); one-way ANOVA followed by Tukey test in (C)). 
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Figure 5 
 
                           
 
Fig. 5: Analysis of DNA methylation in the regulation of TNC expression by 
CIH. (A) Quantification of CpG density and CpG island location proximal to the 
transcriptional start site of the TNC gene with the MethPrimer software. (B) 
Methylation-specific PCR (MSP) targeting the CpG island in the TNC promoter. M, 
methylated DNA; U, unmethylated DNA; ctrl, control; CIH, chronic intermittent 
hypoxia; IVD, in vitro methylated DNA; bp, base pairs. 
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Figure 6 
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Fig. 6: Role of Nrf2 and Nrf3 in oxidative stress-dependent TNC regulation. (A) 
UCSC-integrated ENCODE data proximal to the transcriptional start site of the TNC 
gene. The transcription factor ChIP-sequencing track shows regions of transcription 
factor binding derived from ChIP-seq experiments performed by the ENCODE 
project. The intensity of the grey shading is proportional to the signal strength 
observed in any cell line contributing to the respective cluster. Enrichment levels of 
histone marks (H3K4Me1, H3K4Me3, H3K27Ac) were determined by ChIP-seq and 
indicate regions of active enhancers (H3K4Me1, H3K27Ac) or active promoters 
(H3K4Me3). DNase hypersensitive areas reflect regulatory regions. Further relevant 
TFBS’ found in JASPAR and from published results were added in rectangles [65]. A 
circle shows relevant, additional TFBS’ found in the Swissregulon database. JUN, c-
Jun; ARE, antioxidant response element, targeted by Nrf2 and Nrf3. (B) Nrf2 or (C) 
Nrf3 alone or (D) Nrf2/Nrf3 in combination were knocked down for 48 h followed by 
treatment with 30 µM tBHQ or solvent control (ethanol) for the indicated time points. 
TNC, HO-1, Nrf2 and Nrf3 mRNA levels were determined by RT-qPCR. (E) Cells 
were treated with 10 µM SFN or solvent control (DMSO) and TNC and HO-1 mRNA 
levels were determined by RT-qPCR. (F) TNC and HO-1 mRNA levels were 
determined by RT-qPCR following treatment with 40 µM DMF or solvent control 
(DMSO). n.s., not significant; *, p<0.05; **, p<0.01; ***, p<0.001 (two-way ANOVA 
followed by Bonferroni posttest). 
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Figure 7 
 
                
 
Fig. 7: Role of JNK and c-Jun activity in oxidative stress-dependent TNC 
regulation. (A) Immunoblot analysis of total c-Jun and phosphorylated c-Jun protein 
after treatment with 30 µM tBHQ or solvent control (ethanol) for the indicated time 
points. (B) SUM149PT cells were pre-treated for 1 h with different concentrations of 
the JNK inhibitor SP600125 (SP6) followed by a 9 h treatment with 30 µM tBHQ or 
solvent control (ethanol). Total c-Jun and phosphorylated c-Jun protein was detected 
by immunoblotting. (C) Immunoblot analysis of TNC protein expression in response 
to 30 µM tBHQ with or without 1 h pre-treatment with different concentrations of the 
JNK inhibitor SP600125 for the indicated time points. (D) Quantification of relative 
TNC protein expression levels. (E) Immunoblot analysis of TNC protein levels after 
knockdown of c-Jun for 48 h and followed by treatment with 30 µM tBHQ or solvent 
control (ethanol) for the indicated time points. (F) Quantification of relative TNC 
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protein expression levels. n.s., not significant; **, p<0.01; ***, p<0.001 (one-way 
ANOVA followed by Tukey test). 
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Figure 8 
 
             
 
Fig. 8: Role of NF-κB in oxidative stress-dependent TNC regulation. (A) 
Immunoblot analysis of IκBα protein levels following treatment with 30 µM tBHQ or 
solvent control (ethanol) for the indicated time points. (B) IκBα protein levels were 
analysed by immunoblotting following 1 h pre-treatment with different concentrations 
of the IκB kinase (IKK) inhibitor BAY 11-7082 (BAY) and subsequent addition of 30 
µM tBHQ or solvent control (ethanol) for 9 h. (C) SUM149PT cells were pretreated for 
1 h with 12.5 µM BAY 11-7082 followed by 30 µM tBHQ or solvent control (ethanol) 
for indicated time periods. TNC protein levels were analysed by immunoblotting. (D) 
Quantification of TNC protein levels of the experiment depicted in (C). (E) Following 
transient overexpression of IκBα for 24 h, cells were treated with 30 µM tBHQ or 
solvent control (ethanol) for further 9 h and TNC protein levels were analyzed by 
immunoblotting. (F) SUM149PT cells were treated with 2 ng/ml IL-1β or solvent 
control (0.1% BSA in PBS) for the indicated time course and IκBα and TNC protein 
levels were analyzed by immunoblotting. (G) Analysis of NF-κB binding sites in all 
CIH-upregulated genes, observed in the gene array shown in Supplementary Table 
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S1. The graph depicts the combined results of TFBS identification using the web-
based software oPOSSUM and MetaCore. oPOSSUM and MetaCore identified TFBS 
profiles based on JASPAR and published results, respectively. n.s., not significant; 
***, p<0.001 (one-way ANOVA followed by Tukey test). 
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Figure 9 
 
       
 
Fig. 9: Proposed model of the molecular mechanisms by which intermittent 
hypoxia mediates pro-metastatic gene expression via activation of NF-κB in 
inflammatory breast cancer cells. Intermittent hypoxia upregulates pro-metastatic 
genes in inflammatory breast cancer cells through activation of the transcription 
factor NF-κB. 
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Supplementary Figure 1 
 
        
 
Supplementary Fig. S1: Hypoxia and ROS mediated regulation of a known HIF 
or Nrf2 target gene. (A) Samples shown in Fig. 3D (reoxygenation following 24 h of 
0.2% O2) were analysed for carbonic anhydrase IX (CA9) mRNA levels (a known HIF 
target gene) for the indicated time periods by RT-qPCR. (B) Analysis of heme 
oxygenase (HO-1) mRNA levels (a known Nrf2 target gene) in samples shown in Fig. 
3E (100 mM H2O2 treatment) for the indicated time course by RT-qPCR. (C) Analysis 
of HO-1 mRNA levels in samples shown in Fig. 3F (30 mM tBHQ treatment) for the 
indicated time course by RT-qPCR. **, p<0.01; ***, p<0.001 (one-way ANOVA 
followed by Tukey test for comparisons of treatment to normoxic control in (A); two-
way ANOVA followed by Bonferroni posttest to compare treatment with respective 
control for (B) and (C)). 
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Supplementary Figure 2 
 
            
 
Supplementary Fig. S2: Effects of single and simultaneous knockdown or 
overexpression of Nrf2 and Nrf3 on basal TNC expression. Knockdown of (A) 
Nrf2 or (B) Nrf3 alone or (C) in combination in SUM149PT cells for 48 h followed by 
RT-qPCR analysis of TNC, HO-1, Nrf2 and Nrf3 mRNA levels. Transient 
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overexpression of (D) Nrf2 or (E) Nrf3 alone or (F) in combination for 24 h followed 
by RT-qPCR analysis of TNC, HO-1, Nrf2 and Nrf3 mRNA levels. U6 snRNA served 
as control gene and values were normalized to the average values of normoxic 
controls. (G) Immunoblot analysis for TNC, Nrf2 and Nrf3 in samples from cells with 
transient Nrf2 or Nrf3 overexpression alone or in combination. n.s., not significant; **, 
p<0.01; ***, p<0.001 (Student’s t-test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Manuscript     
	
	
106	
Supplementary Figure 3 
 
                            
 
Supplementary Fig. S3: ROS production in SUM149PT cells following treatment 
with DMF or SFN. Quantification of ROS production with the H2DCFDA assay in 
response to (A) 10 mM SFN or (B) 40 mM DMF. **, p<0.01; ***, p<0.001 (two-way 
ANOVA followed by Bonferroni posttest). 
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Supplementary Figure 4 
 
  
 
Supplementary Fig. S4: Positive correlation between TNC and p105 expression 
in breast cancer transcriptomic data sets. Microarray data from four independent 
studies were compiled and analysed using the R2 genomic analysis tool. TNC mRNA 
levels positively correlate with p105 levels in breast cancer in all studies analysed, as 
assessed by one-way ANOVA. 
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Supplementary Figure 5 
 
       
 
Supplementary Fig. S5: Analysis of TFBS’ in CIH-upregulated genes for AP-1, 
Nrf2 and NF-kB. Upregulated genes of the gene array dataset shown in Fig. 1 were 
analysed for TFBS’ using the web-based oPOSSUM and MetaCore softwares. The 
results of both analyses were combined and are shown as percentage of genes with 
TFBS’ for (A) Nrf2 or (B) AP-1. (C) Genes with TFBS’ for NF-kB, AP-1 and/or Nrf2 
indicated by “+” for a TFBS being present and by “–“ for a TFBS not having been 
found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nrf2
33%
67%
Others
17%
Others
83%
AP-1
NF B/AP-1/Nrf2!
NF B/AP-1/Nrf2!
NF B/AP-1/Nrf2!
NF B/AP-1/Nrf2!
NF B/AP-1/Nrf2!
-   /  +  /  +
+   /  +  /  -
-   /   -   /  -
-   /  +  /  -
+   /  +  /  +
33.3%
30.6%
16.6%
16.7%
2.8%A B C
   Manuscript     
	
	
109	
Supplementary Table S1: Genes upregulated by CIH in inflammatory breast 
cancer cells. 
 
Gene   NCBI accession Gene description     Fold Matrisome  Category  Validated          
Symbol  number            change  Division 
 
MMP9  NM_004994   matrix metallopeptidase 9   51.59 Matrisome-  ECM Regulator X 
associated 
 
SPINK6  NM_205841,  serine peptidase inhibitor,   16.67  
   NM_001195290 Kazal type 6  
 
SERPINB2 NM_001143818, serpin peptidase inhibitor,   14.62 Matrisome-  ECM Regulator  
   NM_002575  clade B (ovalbumin), member 2     associated 
 
TREM1  NM_018643,  triggering receptor      13.47         X 
   NM_001242589,  expressed on myeloid cells 1 
NM_001242590     
 
OLFML3  NM_020190  olfactomedin-like 3     12.00   
 
SERPINB10 NM_005024  serpin peptidase inhibitor,   10.73 Matrisome-  ECM Regulator  
       clade B (ovalbumin), member 10    associated  
 
ADAM19  NM_033274  ADAM metallopeptidase domain 19 8.19  Matrisome-  ECM Regulator X  
          associated 
 
COL6A3  NM_004369,  collagen, type VI, alpha 3   7.08  Core matrisome Collagen 
   NM_057167, 
NM_057166, 
NM_057165,     
   NM_057164     
 
SCARA5  NM_173833  scavenger receptor class A,   6.76  
       member 5 (putative)  
 
NID2  NM_007361  nidogen 2 (osteonidogen)   6.30  Core matrisome ECM Glycoprotein 
 
SHC4  NM_203349  SHC (Src homology 2 domain  6.20          X 
       containing) family, member 4  
 
KPNA7  NM_001145715 karyopherin alpha 7    6.10   
(importin alpha 8) 
 
MMP2  NM_004530,  matrix metallopeptidase 2   5.79  Matrisome-  ECM Regulator X  
NM_001127891           associated 
 
TNC  NM_002160  tenascin C      5.74  Core matrisome ECM Glycoprotein X 
 
A2ML1  NM_144670   alpha-2-macroglobulin- like 1  5.70  Matrisome-  ECM Regulator 
associated 
 
ATP8A2  NM_016529  ATPase, aminophospholipid   5.63   
       transporter, class I, type 8A,  
       member 2   
 
ZNF750  NM_024702  zinc finger protein 750    5.57   
 
IL1A  NM_000575  interleukin 1, alpha     5.49  Matrisome-  Secreted Factor X 
associated 
 
FBN1  NM_000138  fibrillin 1       5.36  Core matrisome ECM Glycoprotein 
 
IL1RN  NM_173842  interleukin 1 receptor antagonist  5.29  Matrisome-   Secreted Factor 
associated  
 
PTGS2  NM_000963  prostaglandin-endoperoxide   6.16          X 
       synthase 2 (prostaglandin  
       G/H synthase and cyclooxygenase) 
 
ODZ2  NM_001122679 odz, odd Oz/ten-m homolog 2  5.11      
 
GINS2  NM_016095  GINS complex subunit 2   5.01  
       (Psf2 homolog)  
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Gene   NCBI accession Gene description     Fold Matrisome  Category  Validated          
Symbol  number            change  Division 
 
VCAN  NM_004385,  versican       4.97  Core matrisome Proteoglycan 
   NM_001164097, 
NM_001164098,  
   NM_001126336    
 
NFE2L3  NM_004289  nuclear factor (erythroid- derived 2)- 4.83          X 
       like 3 
 
ALOX15B NM_001141,  arachidonate 15-lipoxygenase,  4.68   
NM_001039130,  type B  
   NM_001039131   
 
PPP1R14C NM_030949  protein phosphatase 1, regulatory 4.57  
       (inhibitor) subunit 14C 
 
PLA2G4A NM_024420  phospholipase A2, group IVA  4.54   
 
XRCC2  NM_005431  X-ray repair complementing   4.53                     X    
       defective repair in Chinese  
       hamster cells 2   
 
PTHLH  NM_002820,  parathyroid hormone-like hormone 4.52   
NM_198965,    
   NM_198964,  
   NM_198966  
 
SLC26A9 NM_052934,  solute carrier family 26, member 9 4.52   
NM_134325    
 
HS3ST3A1 NM_006042  heparan sulfate(glucosamine)  4.49  
       3-O-sulfotransferase 3A1  
 
KIF4B  NM_001099293 kinesin family member 4B   4.46   
 
CTSL2  NM_001333,  cathepsin L2      4.19   
NM_001201575 
 
ORC1  NM_004153,  origin recognition complex, subunit 1 4.16   
NM_001190818,   
   NM_001190819     
 
POLQ  NM_199420  polymerase (DNA directed), theta  4.05   
  
CXorf49  NM_001145140 chromosome X open reading  4.04   
frame 49 
 
Listed are all at least four-fold upregulated genes in the gene array analysis following CIH in 
SUM149PT cells. Their indicated relation to the matrisome was based on analysis through the 
matrisome project (http://matrisomeproject.mit.edu/proteins/). RT-qPCR validated genes were 
indicated. 
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Supplementary Table S2: TFBS analysis by oPOSSUM and MetaCore for each 
CIH-upregulated gene. 
 
    oPOSSUM analysis      MetaCore analysis 
Gene symbol           RelA    c-Rel     p50      AP-1     Nrf2           RelA    c-Jun 
MMP9     X  X  X  X  X    X  X 
SPINK6      X    
SERPINB2      X    X      X  X 
TREM1      X    X      X  X 
OLFML3    X  X    X  X   
SERPINB10         X    
ADAM19          X      X  
COL6A3    X      X  X   
SCARA5         
NID2     X  X  X  X    
SHC4       X    X    
KPNA7         
MMP2                 X  X 
TNC     X  X  X  X  X    X  X 
A2ML1         
ATP8A2    X  X    X  X   
ZNF750          X    
IL1A           X      X  X 
FBN1     X  X  X  X    
IL1RN     X  X    X      X  
PTGS2                 X  X 
ODZ2     X  X  X  X  X   
GINS2           X    
VCAN     X  X  X  X  X      X 
NFE2L3    X  X  X  X    
ALOX15B          X  X   
PPP1R14C         X    
PLA2G4A                X  X 
XRCC2        
PTHLH     X  X  X  X  X   
SLC26A9    X  X  X  X  X   
HS3ST3A1    X  X    X  X   
KIF4B         
CTSL2         
ORC1       X    X  X   
POLQ           X   
 
Analysis of TFBSs for all CIH-upregulated genes identified by gene array analysis in SUM149PT cells. 
oPOSSUM analysis identified TFBSs for NF-κB (subunits RelA, c-Rel and p50), AP-1 and Nrf2. 
MetaCore analysis identified genes that were reported to be transcriptionally regulated by RelA or c-
Jun (subunit of AP-1) based on manually curated literature. 
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Supplementary Table S3: Primers used for RT-qPCR, MSP-PCR, or BSP-PCR. 
 
RT-qPCR primers 
U6 snRNA forward 5’-CTCGCTTCGGCAGCACA-3’ 
    reverse 5’-AACGCTTCACGAATTTGCGT-3’ 
TNC   forward 5’-GAAGGTGGAGGGGTACAGTG-3’ 
    reverse 5’-TAACGCCCTGACTGTGGTTATT-3’ 
MMP2  forward 5’-CTCGCAAGCCCAAGTGGGACA-3’ 
    reverse 5’-CCATGCTCCCAGCGGCCAAA-3’ 
MMP9  forward 5’-CCCCAGCGAGAGACTCTACA-3’ 
    reverse 5’-CGGAGTAGGATTGGCCTTGG-3’ 
ADAM19  forward 5’-ACCTCGCAGGATGAAAAGGG-3’ 
    reverse 5’-CCGGATGTTCAAGGATCGGT-3’ 
SHC4   forward 5’-ACACTTAGGAGCAGGCAGGA-3’ 
    reverse 5’-TTGCTTCCCTTGTAACTTGGGT-3’ 
Nrf3   forward 5’-TGACTGGGAGGCAGAAAAGA-3’ 
  reverse 5’-TCAGGCTGTGATGAAAGCAAC-3’ 
HO-1   forward 5’-ATGACACCAAGGACCAGAGC-3’ 
    reverse 5’-GTGTAAGGACCCATCGGAGA-3’ 
CA9   forward 5’-ACCAGACAGTGATGCTGAGTG-3’ 
    reverse 5’-AAACCAGGGCTAGGATGTCAC-3’ 
Nrf2   forward 5’-GGATCTGCCAACTACTCCCAG-3’ 
    reverse 5’-GACTGAAACGTAGCCGAAGA-3’ 
IL1A   forward 5’-GATCAGTACCTCACGGCTGC-3’ 
    reverse 5’-GTGCCGTGAGTTTCCCAGAA-3’ 
TREM1  forward 5’-TCCTCCTACCACCACTAAGGC-3’ 
    reverse 5’-CATTCTCGTGGGTTCGTGGG-3’ 
COX-2  forward 5’-CAACTCTATATTGCTGGAACATGGA-3’ 
    reverse 5’-TGGAAGCCTGTGATACTTTCTGTACT-3’ 
 
MSP primers 
TNC-methylated   forward 5’-TATAAGAGGGGAGTTAGGGTTGC-3’ 
reverse 5’-AAACCCATTTACATACAATTTATAACGA-3’ 
TNC-unmethylated  forward 5’-AGTATAAGAGGGGAGTTAGGGTTGT-3’ 
reverse 5’-AAACCCATTTACATACAATTTATAACAAA-3’ 
 
BSP primers 
TNC promoter  
  forward   5’-TGTAAAACGACGGCCAGTTTTTTTTAGGAATTGGGTTTAG-3’ 
  reverse   5’-CAGGAAACAGCTATGACCTTTCCCACTTTTTCAATTAACR-3’ 
TNC 1st exon 
  forward   5’-TGTAAAACGACGGCCAGATTGAAAAAGTGGGAAAGGAT-3’ 
  reverse   5’-CAGGAAACAGCTATGACCCAACRATAAAAAAAAAAACCCC-3’ 
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4. Unpublished data 1: Effect of chronic intermittent hypoxia- 
conditioning on the malignant properties of SUM149PT 
inflammatory breast cancer cells  
 
INTRODUCTION 
The oxygen levels in tumors are dynamic, with repeated cycles of hypoxia and 
reoxygenation, called intermittent hypoxia (IH). IH has been shown to promote tumor 
progression, metastasis and treatment resistance (Durand, 2001; Durand & Aquino-
Parsons, 2001a; Martinive et al., 2006; Rofstad, Gaustad, Egeland, Mathiesen, & 
Galappathi, 2010). While inflammatory breast cancer (IBC) is rare, it is the most 
aggressive form of breast cancer (Anderson, Schairer, Chen, Hance, & Levine, 2005; 
Hance, Anderson, Devesa, Young, & Levine, 2005). The mechanisms leading to the 
aggressiveness of IBC are poorly understood. IBC does not occur as a single solid 
tumor, but is rather diffusely distributed and metastasizes rapidly (Silvera & 
Schneider, 2009; Yang et al., 2008). IBC is highly proliferative (Paradiso et al., 1989), 
highly angiogenic, and displays a higher intratumoral microvessel density than non-
IBC tumors (Colpaert et al., 2003; McCarthy et al., 2002). Comparing gene 
expression between IBC and non-IBC revealed a more abundant expression of pro-
angiogenic and hypoxia regulated genes in IBC, such as vascular endothelial growth 
factor A (VEGFA) and prostaglandin G/H synthase 2 (PTGS2/COX2) (Bieche et al., 
2004). Furthermore, IBC tumor blood vessels are not fully developed (Vermeulen, 
van Golen, & Dirix, 2010). This suggests that IBC cells are exposed to IH. Silvera 
and Schneider further postulated that IBC cells have adapted to the hypoxic 
microenvironment by changing gene expression (Silvera & Schneider, 2009).  
The role of IH in IBC and its impact on tumor progression is unclear. Therefore, we 
investigated the effect of chronic IH (CIH) on cancer cell malignant properties in the 
IBC cell line SUM149PT, performing different in vitro assays used to determine 
changes in the behavior of cancer cells.  
 
MATERIAL AND METHODS 
Cell culture and treatments 
The human triple-negative breast cancer cell line SUM149PT was cultured in equal 
parts of high-glucose DMEM (Sigma-Aldrich) and Ham's F-12 Nutrient Mixture 
(Gibco, Thermo Fischer Scientific, Waltham, MA, USA), supplemented with 5% heat-
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inactivated fetal bovine serum (FBS), 1 µg/ml hydrocortisone (Sigma-Aldrich), 5 
µg/ml human insulin (Sigma-Aldrich), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Sigma-Aldrich). H2O2 (Sigma-Aldrich) was diluted to the required concentration in 
DMEM/F-12 medium without FBS and supplements. Hypoxic experiments were 
carried out in a humidified atmosphere containing 0.2% O2 and 5% CO2 in a gas-
controlled glove box (Invivo2 400, Baker Ruskinn, Bridgend, UK). For the CIH 
conditioning, cells were cultured for 20 cycles in CIH conditions (24 h 0.2% O2, 48 h 
21% O2). In parallel, cells were cultured under standard normoxic conditions for the 
same duration of time. Scratch assays were performed directly following 20 cycles of 
CIH. For all other assays, CIH-conditioned cells have been frozen, were then thawed, 
and after some days of cell expansion, they were cultured again for 2-20 cycles in IH 
conditions before performing experiments. 
 
Scratch assay 
Cells were grown to full confluency in 6-well plates. Two straight lines were scratched 
with a 200 µl pipette tip, forming a cross. Microscopic images were taken directly and 
following 15 hours of cultivation under standard culture conditions. The cell-free area 
was measured using ImageJ 1.48v (http://imagej.nih.gov/ij) and converted to 
percentage scratch recovery. 
 
Proliferation assay 
To determine cell proliferation 8x104 cells were seeded per well into 12-well dishes. 
Cells were cultivated in normoxia for up to 72 hours. Following 24, 48 and 72 hours 
cells were detached by trypsin/EDTA. Viable cells were counted via trypan blue 
exclusion using a Beckman Coulter Vi-cell XR Cell Viability Analyser (Brea, CA, 
USA).  
 
Viability assays 
To determine the impact of different stimuli on cell viability and cell proliferation, 
1.6x105 cells per well were seeded into 12-well dishes. For H2O2 experiments, cells 
were treated with different concentrations of H2O2 for 24 hours. For transient nutrient 
deprivation experiments, cells were cultivated in PBS for 6 hours, followed by 
cultivation in normal medium for 24 hours. For the comparison of normoxia and 
hypoxia, cells were cultivated for 48 hours in normoxia or hypoxia. Supernatant was 
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collected and cells were detached by trypsin/EDTA. Cell counting and determination 
of cell viability was performed via trypan blue exclusion using a Beckman Coulter Vi-
cell XR Cell Viability Analyser.  
 
Attachment assay 
96-well plates were coated with Poly-L-Lysine (Sigma-Aldrich), collagen 1 (Sigma-
Aldrich), fibronectin (Sigma-Aldrich), or left untreated. 2x104 cells were seeded per 
well and incubated for 30 min under standard culture conditions. Following shaking 
and washing in order to remove non-attached cells, attached cells were fixed and 
stained with crystal violet. 
 
H2DCFDA assay 
SUM149PT cells were seeded in 96-well plates at 80% confluency and incubated 
with 10 µM 2'7'-dichlorodihydrofluorescein diacetate (H2DCFDA, Invitrogen) for 30 
min in the dark. Subsequently, specific treatments were performed and fluorescence 
was measured using a 96-well fluorescence photometer (Infinite 200Pro, Tecan, 
Männedorf, Switzerland). Results were calculated as increase in fluorescence per 
well ((Ftx – Ft0) / Ft0*100), where Ftx = fluorescence at a certain time point and Ft0 = 
fluorescence at 0 min (Wang & Joseph, 1999). For hypoxia-reoxygenation 
experiments, 96-well plates were incubated for 24 h in 0.2% oxygen. Cells were 
incubated with H2DCFDA inside the hypoxia workstation and fluorescence 
measurements were performed immediately thereafter. 
 
Statistical analyses 
Results are presented as mean values ± standard error of the mean (SEM). 
Statistical analyses were performed using one-way ANOVA followed by Tukey`s 
Multiple Comparison Test. P-values < 0.05 were considered statistically significant. 
 
RESULTS 
Effect of CIH on the migratory and proliferative potential of SUM149PT cells 
To investigate the effect of CIH on tumor aggressiveness in IBC, the IBC cell line 
SUM149PT was cultured for 20 cycles in CIH conditions (24 h 0.2% O2, 48 h 21% 
O2). In parallel, SUM149PT cells were cultured under standard normoxic conditions 
(Ctrl). For subsequent assays, SUM149PT cells which were cultured only for a short 
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time period (Untreated) were included in order to determine changes that occurred 
due to long-term cultivation. 
In order to analyze the effect of CIH on cell migration, scratch assays were 
performed. Scratch recovery occurred quickly compared to the ER-positive breast 
cancer cell line T47D (see Unpublished data 2) and neither CIH nor long-term 
cultivation caused changes in the migratory potential of SUM149PT cells (Figure 1A). 
Proliferation assays were performed in order to investigate if CIH led to enhanced 
cell divisions of SUM149PT cells. Over a time course of 72 hours, neither CIH nor 
long-term cultivation caused changes in the proliferative potential of SUM149PT cells 
(Figure 1B). Both assays were performed independently only twice, as we observed 
no differences. 
 
                  
Figure 1: Effect of chronic intermittent hypoxia (CIH) on migratory and proliferative potential of 
SUM149PT cells. (A) Scratch assay to compare migratory potential of CIH-conditioned cells (CIH) 
with their respective normoxic control cells (Ctrl) and with cells that were only cultured for a short time 
period (Untreated) (n=2). (B) Proliferation of CIH-conditioned cells (CIH), their respective normoxic 
control cells (Ctrl) and cells that were cultured for a short time period (Untreated) (n=2). 
 
Effect of transient nutrient deprivation, hypoxia and oxidative stress on cell 
viability and proliferation in CIH-conditioned and control cells 
Under CIH conditions, tumor cells in vivo are exposed to hypoxia and/or oxidative 
stress. Moreover, due to the fluctuations in blood flow nutrient and growth factor 
delivery is insufficient and does not match the metabolic requirements. Therefore, we 
aimed to investigate if cells cultivated in CIH conditions in vitro, adapt to the before 
mentioned conditions.  
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Cells were treated for 24 hours with increasing concentrations of H2O2 as an 
oxidative stress stimulus. The effect on cell proliferation and cell viability was 
analyzed. 1 mM H2O2 caused a decrease in cell viability and was therefore toxic to 
SUM149PT cells (Figure 2A). H2O2 concentrations below 1 mM had no effect on cell 
viability but caused a decrease in the number of viable cells, hence showing an 
inhibitory effect on cell proliferation (Figure 2A). However, the observed effects were 
not statistically significant comparing CIH-conditioned cells with their respective 
normoxic controls and their short-term cultivation controls (Figure 2A).  
In order to determine the effect of a transient nutrient deprivation in SUM149PT cells, 
cells were cultured for 6 hours in PBS, followed by cultivation in normal medium for 
24 hours. Transient nutrient deprivation had no effect on cell viability, but cell 
proliferation was reduced by about 50% (Figure 2B). However, there was no 
statistically significant difference between CIH-conditioned cells, their respective 
normoxic controls and their short-term cultivation controls (Figure 2B).  
With the purpose to compare cell proliferation and cell viability in normoxia and 
hypoxia, cells were cultivated for 48 hours in normoxic or hypoxic conditions. 
Cultivation in hypoxic conditions had no effect on viability or cell proliferation of 
SUM149PT cells (Figure 2C). Further, no difference could be observed between CIH-
conditioned cells, their respective long-term cultivation control cells and their short-
term cultivation control cells (Figure 2C). 
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Figure 2: Effect of H2O2, nutrient deprivation or hypoxia on proliferation and viability in 
SUM149PT CIH-conditioned cells (CIH) their respective control cells (Ctrl) and short-term 
cultivated control cells (Untreated). (A) Cells were treated with different concentrations of H2O2 for 
24 hours. Cell number and cell viability was assessed (n=3). ns, not significant; *p<0.05. (B) Cells 
were cultured for 6 hours in PBS, followed by cultivation in normal medium for 24 hours. Cell number 
and cell viability was assessed (n=3). ns, not significant. (C) Cells were cultured for 48 hours in 
normoxic or hypoxic conditions. Cell number and cell viability was assessed (n=3). ns, not significant. 
 
Effect of CIH on stimuli-dependent intracellular ROS generation 
Chronic intermittent hypoxia is widely considered as a source of intracellular reactive 
oxygen species (ROS) (Dewhirst, Cao, & Moeller, 2008; Nanduri, Yuan, Kumar, 
Semenza, & Prabhakar, 2008). Therefore, we aimed to assess if CIH-conditioned 
cells have adapted to ROS. H2DCFDA assays were performed in order to determine 
the level of ROS generation during 30 min of reoxygenation (following 24 hours in 
hypoxia) in SUM149PT cells. Cells were also treated with 100 µM H2O2 and the 
change in DCF fluorescence during 30 min of treatment was determined. Further, the 
reoxygenation stimulus was combined with the H2O2 treatment. All treatments 
caused an increase in DCF fluorescence. While H2O2 treatment had the lowest 
effect, the combined treatment of H2O2 and reoxygenation showed the highest 
increase in DCF fluorescence (Figure 3). Comparing the response of CIH-
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conditioned cells with the response of their respective control cells and the response 
of the short-term cultivated cells, no significant difference was detected (Figure 3).  
 
                                       
Figure 3: Comparison of stimuli-dependent intracellular ROS generation in CIH-conditioned 
cells (CIH), their respective control cells (Ctrl) and short-term cultivated control cells 
(Untreated). H2DCFDA assays were performed to quantify the generation of intracellular ROS levels 
by treatment with 100 µM H2O2, upon reoxygenation and upon combined reoxygenation and treatment 
with 100 µM H2O2 over 30 minutes (n=3-4). ns, not significant. 
 
Effect of CIH on cell attachment 
We observed a CIH-mediated upregulation of genes encoding for extracellular matrix 
(ECM) proteins (see chapter 3: Manuscript). This might mediate differential 
attachment properties of SUM149PT cells towards different ECM components. 
Therefore, attachment assays were performed in order to investigate the cell 
attachment to collagen 1 and fibronectin. Cells were seeded on coated cell culture 
dishes and allowed to attach for 30 minutes. Shaking and washing removed non-
attached cells. Poly-L-lysine is a nonspecific attachment factor that promotes cell 
attachment by enhancing the electrostatic interaction between negatively charged 
ions of the cell membrane and the culture dish surface and was therefore used for 
normalization of the results observed for attachment to collagen 1 and fibronectin. 
The highest level of cell attachment occurred with collagen 1, while there was no 
difference between CIH-conditioned and control cells (Figure 4). Investigating the 
attachment to fibronectin, CIH-conditioned cells showed the highest level of 
attachment, which was significantly different compared to short-term cultured control 
cells. However, compared to their respective long-term cultured control cells, the 
difference was not significant (Figure 4). 
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Figure 4: Comparison of attachment to different substrates of CIH-conditioned cells (CIH), their 
respective control cells (Ctrl) and short-term cultivated control cells (Untreated). Cell 
attachment assays were performed to determine the level of cell attachment to poly-L-lysine, collagen 
1 or fibronectin (n=4). *p<0.05; ns, not significant. 
 
DISCUSSION 
CIH has been linked to tumor progression and tumor aggressiveness in various 
tumor models (Durand & Aquino-Parsons, 2001b; Rofstad et al., 2010). However, so 
far the impact of CIH on tumor progression in inflammatory breast cancer has not 
been investigated. Here, we studied the effect of CIH on cancer cell malignant 
properties in the inflammatory breast cancer cell line SUM149PT. Gene expression 
analysis revealed an enhanced expression of pro-metastatic genes following CIH 
(see chapter 3: Manuscript). This could suggest that these changes transfer into a 
more aggressive phenotype of SUM149PT cells. Therefore, various in vitro assays 
were performed in order to determine if CIH changes the malignant properties of 
SUM149PT cells.  
We could detect a trend towards a differential attachment behavior upon CIH, as 
observed on fibronectin-coated dishes. This is in accordance with the identified 
enhanced expression of ECM proteins, suggesting ECM remodeling and hence 
differential attachment characteristics. Here, we only studied the attachment to 
collagen I and fibronectin. For further evaluation of the attachment characteristics the 
assay should be extended with additional ECM components as coating substrates, 
such as laminin or fibrillin, or with a combination of different substrates. 
In all other performed assays we did not observe significant CIH-mediated changes 
in the malignant properties of SUM149PT cells. There are different factors to 
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consider while interpreting these results. The first point to take into consideration is 
that only the scratch assay was performed directly following 20 cycles of CIH and 
therefore also in close time proximity to the sample collection for gene expression 
analyses (see chapter 3: Manuscript). For all other experiments, CIH-conditioned 
cells have been first frozen, were then thawed, and after some days of cell expansion 
they were cultured again in IH conditions before performing experiments. Even 
though the cells were cultured for at least two cycles in IH conditions before 
performing further experiments, the interrupted cultivation and especially the process 
of freezing and thawing, might have reversed the observed CIH-mediated changes in 
gene expression and the potential behavioral changes. The second point to consider 
is that IBC is the most aggressive and most lethal form of breast cancer (Fouad, 
Kogawa, Reuben, & Ueno, 2014). SUM149PT cells were isolated from a patient with 
triple negative IBC. Hence, these cells host already very aggressive features, which 
we also observed with the performed in vitro assays. Scratch recovery in a scratch 
assay occurred very rapidly compared to T47D cells (see chapter 5: Unpublished 
data 2). Furthermore, SUM149PT cells showed a resistance to high levels of 
oxidative stress, whereby only a H2O2 concentration of 1 mM showed a toxic effect. 
Further, neither transient nutrient deprivation nor hypoxia had a negative effect on 
cell viability. Cultivation in hypoxia for two days did not even inhibit cell proliferation. 
This is in accordance with the findings of Silvera and Schneider (Silvera & Schneider, 
2009) who exposed SUM149PT cells to hypoxia for 24 hours and found them to be 
highly resistant to protein synthesis inhibition, especially in comparison with the non-
transformed MCF10A cells. Considering this highly aggressive phenotype of 
SUM149PT cells, it is reasonable to assume that CIH did not cause a major 
additional enhancement in aggressiveness, which could have been detected with the 
in vitro assays performed herein. In vivo assays might give different results. This was 
e.g. observed by Herrmann et al. (Herrmann et al., 2015), where hypoxic 
preconditioning of neuroblastoma cells caused a more aggressive phenotype in vivo, 
while in vitro no differences could be detected. In order to analyze the impact of CIH 
on mediating phenotypic changes relevant for tumor progression, it should be further 
considered to use a non-tumorigenic cell line, like the spontaneously immortalized 
human breast epithelial cell line MCF-10A (Soule et al., 1990).  
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5. Unpublished data 2: Effect of chronic intermittent hypoxia on 
gene expression and cancer cell malignant properties in T47D cells 
 
INTRODUCTION 
In the previous chapters, we analyzed the effect of chronic intermittent hypoxia (CIH) 
on gene expression and cancer cell behavior in the triple-negative inflammatory 
breast cancer (IBC) cell line SUM149PT. Here, we aimed to study the impact of CIH 
on transcriptional regulation and cancer cell malignant properties in a non-IBC cell 
line, and selected the estrogen receptor-positive breast cancer cell line T47D.  
 
MATERIAL AND METHODS 
Cell culture and treatments 
The human breast cancer cell line T47D was cultured in high-glucose DMEM (Sigma-
Aldrich), supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 
U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Hypoxic experiments 
were carried out in a humidified atmosphere containing 0.2% O2 and 5% CO2 in a 
gas-controlled glove box (Invivo2 400, Baker Ruskinn, Bridgend, UK). For the CIH 
experiment, cells were cultured for 20 cycles in CIH conditions (24 h 0.2% O2). In 
parallel, cells were cultured under standard normoxic conditions for the same 
duration of time. 
 
mRNA analysis and data deposition 
The RNeasy mini kit (Qiagen, Hilden, Germany) was used for total RNA extraction 
according to manufacturer’s protocol. Affymetrix Human Gene 2.1 ST strip arrays 
were used by the Functional Genomics Center Zurich (FGCZ) to analyze transcript 
levels of one biological replicate of untreated cells and of cells cultured for 60 days in 
CIH. For validation of the Affymetrix gene array results, three biological replicates of 
untreated cells and cells that were cultured for 60 days in normoxia or CIH conditions 
were analyzed by RT-qPCR. cDNA synthesis was based on 1 µg RNA using M-MLV 
Reverse Transcriptase (Promega Corporation, Madison, WI, USA) according to 
Manufacturer’s recommendation. Reverse transcription-quantitative PCR (RT-qPCR) 
was performed with Roche SYBR Green 1 Master (Roche Diagnostics Ltd., 
Rotkreuz, Switzerland) and samples were analyzed on the LightCycler480 Instrument 
II (Roche Diagnostics Ltd.). The relative mRNA expression was quantified with the 
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LightCycler480 quantification software. U6 snRNA served as control gene and values 
were normalized to the average values of normoxic controls. Primer sequences are 
listed below: 
Gene name Forward primer (5`-3`) Reverse primer (5`-3´) 
U6  CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
STC1 AGTGGCGGCTCAAAACTCA TGACGAATGCTTTTCCCTGA 
SULF1 ACTGTACCCCAATGCTTCCC GCATGTTATACAGCCTCTCCAC 
 
Scratch assay 
Cells were grown to full confluency in 6-well plates. Two straight lines were scratched 
with a 200 µl pipette tip, forming a cross. Microscopic images were taken directly and 
following 24 and 48 hours of cultivation under standard culture conditions. The cell-
free area was measured using ImageJ 1.48v (http://imagej.nih.gov/ij) and converted 
to percentage scratch recovery. 
 
Proliferation assay 
To determine cell proliferation, cells were cultivated in normoxia for up to 72 hours. 
Following 24, 48 and 72 hours, the number of viable cells was estimated by using an 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolim) assay (Cell Titer Aqueous, Promega, Madison, WI, USA) according to the 
manufacturer’s protocol.  
 
Statistical analyses 
If not otherwise indicated, results are presented as mean values ± standard error of 
the mean (SEM). Statistical analyses were performed using Student’s t-test or one-
way ANOVA followed by Tukey’s Multiple Comparison Test where appropriate. P-
values < 0.05 were considered statistically significant. 
 
RESULTS 
Effect of CIH on gene expression in T47D cells 
In order to investigate the effect of CIH on gene expression and cancer cell behavior 
in a non-IBC cell line, the human estrogen receptor-positive breast cancer cell line 
T47D was cultured for 20 cycles in CIH conditions (24 h 0.2% O2, 48 h 21% O2). As 
control, T47D cells were cultured in parallel under standard normoxic conditions 
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(Figure 1). Gene expression of untreated cells and cells that were cultured in CIH 
conditions for 60 days was assessed by whole genome microarray hybridization. 53 
genes showed to be more than 2-fold upregulated following CIH with the highest fold 
change of 8. 20 genes showed to be more than 2-fold downregulated following CIH 
with the highest negative fold change of 4. 
 
                        
Figure 1: Experimental scheme of the CIH time schedule, indicating the duration of exposure to 
hypoxia and normoxia, and the time points of sample collection. 
 
The CIH experiment was repeated to validate the expression levels of one up- and 
one down-regulated candidate gene, which were chosen because they are known to 
play a possible role in tumor progression. Expression of stanniocalcin 1 (STC1) 
showed to be 3-fold upregulated following CIH. STC1 encodes for a secreted 
glycoprotein and has been linked to tumor progression. High STC1 expression in 
tumor samples has been correlated to a poor prognostic outcome (McCudden, 
Majewski, Chakrabarti, & Wagner, 2004). STC1 overexpressing cells showed 
enhanced proliferation and migration (Liu et al., 2010). Expression of sulfatase 1 
(SULF1) was 2-fold downregulated following CIH. SULF1 encodes for an 
extracellular heparan sulfate endosulfatase. SULF1 selectively removes 6-O-sulfate 
groups from heparan sulfate chains of heparan sulfate proteoglycans (HSPGs), a key 
constituent of the extracellular matrix (Morimoto-Tomita, Uchimura, Werb, 
Hemmerich, & Rosen, 2002). SULF1 expression is decreased in multiple malignant 
lineages, and its re-expression is known to be associated with decreased signaling of 
heparin-binding growth factors, cell proliferation and the invasiveness of cancer cells 
(Abiatari et al., 2006; Lai et al., 2003; Lai et al., 2004).  
Gene expression of these genes was analyzed in response to hypoxia, 
reoxygenation (both part of cycle 1 of the CIH experiment; Figure 1) and CIH (20 
cycles; Figure 1). STC1 and SULF1 showed no significant regulation in response to 
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hypoxia or in response to a single reoxygenation stimulus, but following 20 cycles of 
CIH, STC1 was significantly upregulated (Figure 2A) and SULF1 was significantly 
downregulated (Figure 2B). 
 
                
Figure 2: Gene array validation identifies genes regulated by CIH. (A+B) Validation of gene array 
results for selected candidate genes in T47D cells by RT-qPCR (n=3). *p<0.05; **p<0.01; Student’s t-
test. 
 
Effect of CIH on migratory and proliferative potential of T47D cells 
Scratch and proliferation assays were performed to compare the phenotype of cells 
that were cultured in CIH conditions with their respective normoxic controls (Ctrl). 
Comparisons were also carried out with T47D cells that were cultured only for a short 
time period (Untreated) in order to determine changes that occurred due to long-term 
cultivation. 
Scratch assays were performed in order to analyze the effect of CIH on cell 
migration. Scratch recovery occurred slowly compared to SUM149PT cells (see 
chapter 4: Unpublished data 1). After 48 hours, scratches recovered by 70% and 
neither CIH nor long-term cultivation caused changes in the migratory potential of 
T47D cells (Figure 3A). Proliferation assays were performed in order to investigate 
the impact of CIH on cell proliferation. Only one of the two independently performed 
experiments showed an enhanced proliferation over a time course of 72 hours 
(Figure 3B). Hence, additional independent experiments would be needed to draw a 
final conclusion. 
 
0
1
2
3
4
**
re
la
ti
v
e
m
R
N
A
le
v
e
ls
0.0
0.5
1.0
1.5
2.0
2.5
*
re
la
ti
v
e
m
R
N
A
le
v
e
ls
Cycle 1 CIH
Normoxia
Hypoxia
Reoxygenation
STC1 SULF1
Normoxia
Hypoxia
Reoxygenation
Cycle 1 CIH
A B
  Unpublished data 2 
	 128	
              
Figure 3: Effect of chronic intermittent hypoxia (CIH) on migratory and proliferative potential of 
T47D cells. (A) Scratch assay to compare migratory potential of CIH-conditioned cells (CIH) with their 
respective normoxic control cells (Ctrl) and with cells that were only cultured for a short time period 
(Untreated) (n=3). ns, not significant; one-way ANOVA followed by Tukey’s Multiple Comparison Test. 
(B) Proliferation of CIH-conditioned cells (CIH), their respective normoxic control cells (Ctrl) and cells 
that were cultured for a short time period (Untreated) (n=2). 
 
DISCUSSION 
Here, we analyzed the effect of CIH on gene expression and cancer cell malignant 
properties in the estrogen receptor-positive breast cancer line T47D. T47D cells were 
cultured in CIH conditions and gene array analysis revealed changes in gene 
expression following CIH. Validation of the results in three independent experiments 
confirmed an upregulated expression of STC1 following CIH. A high expression of 
STC1 has been linked to a poor prognostic outcome and to the promotion of tumor 
progression (Liu et al., 2010; McCudden et al., 2004). Further, we could confirm a 
downregulated expression of SULF1. A low expression of SULF1 was found in 
different tumor entities and has been linked tumor progression (Abiatari et al., 2006; 
Lai et al., 2003; Lai et al., 2004). These findings indicate that CIH is an important 
regulator of cancer progression, which is mediated by the upregulation of oncogenes 
and/or downregulation of tumor suppressor genes. Upon identifying changes in gene 
expression, which suggested a translation into a more aggressive phenotype of T47D 
cells following CIH, different in vitro assays were performed. Analyzing the migratory 
potential, we could not observe any changes following CIH. Performing proliferation 
assays, suggested a trend towards an enhanced proliferation following CIH, but as 
only one of the two performed experiments showed an enhanced proliferation, 
additional independent experiments, as well as different in vitro and in vivo assays 
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would be needed in order to fully investigate the role of CIH on cancer cell malignant 
properties.  
 
 
REFERENCES 
Abiatari, I., Kleeff, J., Li, J., Felix, K., Buchler, M. W., & Friess, H. (2006). Hsulf-1 
regulates growth and invasion of pancreatic cancer cells. Journal of Clinical 
Pathology, 59(10), 1052–1058. 
Lai, J., Chien, J., Staub, J., Avula, R., Greene, E. L., Matthews, T. A., et al. (2003). 
Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. 
Journal of Biological Chemistry, 278(25), 23107–23117.  
Lai, J.-P., Chien, J., Strome, S. E., Staub, J., Montoya, D. P., Greene, E. L., et al. 
(2004). HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in 
head and neck squamous carcinoma. Oncogene, 23(7), 1439–1447.  
Liu, G., Yang, G., Bin Chang, Mercado-Uribe, I., Huang, M., Zheng, J., et al. (2010). 
Stanniocalcin 1 and ovarian tumorigenesis. Journal of the National Cancer 
Institute, 102(11), 812–827.  
McCudden, C. R., Majewski, A., Chakrabarti, S., & Wagner, G. F. (2004). Co-
localization of stanniocalcin-1 ligand and receptor in human breast carcinomas. 
Molecular and Cellular Endocrinology, 213(2), 167–172.  
Morimoto-Tomita, M., Uchimura, K., Werb, Z., Hemmerich, S., & Rosen, S. D. (2002). 
Cloning and characterization of two extracellular heparin-degrading 
endosulfatases in mice and humans. Journal of Biological Chemistry, 277(51), 
49175–49185.  
 
  Conclusions and future perspectives 
	 130	
6. Conclusions and future perspectives 
 
Cancer is one of the biggest threats to our society with most of cancer-related deaths 
resulting from metastatic cancers. Breast cancer is the most common cancer in 
women worldwide and the second most common cancer overall (Ferlay et al., 2015). 
Much progress has been made in the fight against cancer, which includes an earlier 
diagnosis and better therapies. Still, many improvements are needed in the 
development of targeted therapies and especially in the treatment of metastatic 
disease. 
In this thesis, we analyzed the role of chronic intermittent hypoxia (CIH) on breast 
cancer cell gene expression and malignant properties. The human triple-negative 
inflammatory breast cancer (IBC) cell line SUM149PT and the estrogen receptor-
positive breast cancer cell line T47D were exposed to intermittent hypoxia (24 h 0.2% 
O2, 48 h 21% O2) for two month.  
In vitro assays were performed in order to identify CIH-mediated changes in the 
behavior of SUM149PT and T47D cells. In SUM149PT cells, we observed a trend 
towards a differential attachment behavior following CIH. In all further performed 
assays, we could not observe significant changes in the cancer cell behavior. This 
might have different reasons. For example, SUM149PT cells origin from a patient 
with IBC and IBC is the most aggressive form of breast cancer. Hence, SUM149PT 
cells host already very aggressive features and one could assume that CIH did not 
cause a major additive enhancement in aggressiveness, which could have been 
detected with the performed in vitro assays.  
The effects of CIH on the transcriptomic profile were analyzed in order to get insights 
into the signaling pathways which might be involved in the repeatedly reported 
enhancement of tumor aggressiveness upon intermittent hypoxia.  
Chronic intermittent hypoxia (CIH) caused changes in gene expression in both cell 
lines, yet the observed changes did not overlap. Triple negative and ER-positive 
breast cancers have particular and opposing characteristics. As basal gene 
expression differs completely between these two cell lines, it is not surprising that the 
observed changes in gene expression were also different. Further, the number of 
differentially expressed genes was much higher in SUM149PT cells than in T47D 
cells. In SUM149PT cells, 531 protein-coding genes were more than 2-fold 
upregulated, while 379 genes were more than 2-fold downregulated. In T47D cells, 
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the number of differentially expressed genes was 10 times lower. In T47D cells, we 
positively validated the CIH-mediated differential expression of two extracellular 
matrix (ECM) proteins, which have been linked to tumor progression. Further 
analyses focused on SUM149PT cells, as inflammatory breast cancers have a much 
worse prognosis than ER-positive ones and hence further understanding of the 
disease is vital in order to develop better therapies. In SUM149PT cells, CIH caused 
a strong upregulation of pro-metastatic genes encoding ECM proteins and proteins 
involved in inflammatory processes. We identified an upregulated expression of 
matrix remodeling proteases, like the matrix metalloproteinases MMP2 and MMP9, 
and further ECM components like tenascin-C (TNC), versican, fibrillin, nidogen and 
collagen type VI. This suggests that CIH promotes changes in gene expression 
which may result in ECM remodeling, supporting tumor progression, particularly 
invasion and metastasis formation. We further confirmed an upregulated expression 
of tenascin-C upon intermittent hypoxia on mRNA and protein level. High levels of 
TNC have been linked to poor prognosis (Yoshida, Ishihara, Hirokawa, Kusakabe, & 
Sakakura, 1995), local and distant recurrence in breast carcinomas (Jahkola et al., 
1998; Minn et al., 2005) and metastasis formation (Midwood, Hussenet, Langlois, & 
Orend, 2011; Orend, 2005; Saupe et al., 2013).  
As TNC is a key factor in tumor progression, we focused on analyzing the signaling 
pathways that cause the elevated expression of TNC mediated by CIH. The 
oscillating changes in tissue oxygen availability during CIH are a source of oxidative 
stress due to reactive oxygen species (ROS) generation (Dewhirst, Cao, & Moeller, 
2008). Hence, we decided to study the role of oxidative stress in TNC regulation. In 
fact, we could identify for the first time an oxidative stress mediated regulation of 
TNC in inflammatory breast cancer cells, which was dependent on activation of the 
NF-κB but not of other redox signaling pathways. Reports linking oxidative stress and 
TNC regulation are very rare. The only study showing a direct link between oxidative 
stress (H2O2 stimulation) and TNC regulation was performed in rat cardiac myocytes 
(Yamamoto et al., 1999). A few other studies postulated an indirect link between 
oxidative stress and TNC regulation (Aziz et al., 1997; Eba et al., 2013; Zou et al., 
2013). However, to our knowledge there is no study reporting an oxidative stress 
mediated TNC regulation in breast cancer cells. Further, we could support an NF-κB 
dependent TNC regulation in inflammatory breast cancer cells by treating 
SUM149PT cells with Il-1β. Il-1β stimulation caused a strong induction of TNC protein 
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levels. Various reports exist showing TNC inducibility upon stimulation with IL-1α, IL-
1β, TNF-α or LPS (Goh, Piccinini, Krausgruber, Udalova, & Midwood, 2010; Luo et 
al., 2015; Maqbool et al., 2013; Sarközi et al., 2015). However, none of the studies 
was performed in breast cancer cells. 
 
Tumor inflammation has also been associated with cancer progression and 
metastasis formation and we observed an upregulated expression of proteins 
involved in inflammatory processes following CIH. Hanahan and Weinberg added the 
tumor-promoting inflammation as a new “enabling characteristic” to their original 
description of the hallmarks of cancer. This tumor-promoting inflammation contributes 
to the acquisition of other hallmarks by supplying bioactive molecules to the tumor 
microenvironment, including growth factors, pro-angiogenic factors and matrix-
modifying enzymes (Hanahan & Weinberg, 2011). 
TNC has been shown to activate toll-like receptor 4, followed by NF-κB activation 
and induction of pro-inflammatory cytokines and of TNC itself. TNC has been 
identified to drive the persistent joint inflammation observed in rheumatoid arthritis 
(Midwood et al., 2009). Further, TNC has been shown to drive the persistence of 
organ fibrosis in systemic sclerosis via toll-like receptor 4 (Bhattacharyya et al., 
2016). Hence, dysregulated TNC may promote an autocrine loop leading to chronic 
inflammation in autoimmune diseases as well as in cancer.  
In endothelial cells, IH has been shown to amplify a tumor-promoting pro-
inflammatory phenotype with increased expression of inflammatory cytokines 
mediated via NF-κB activation (Tellier et al., 2015). CIH might also play an important 
role in IBC. Several studies indicated NF-κB to be constitutively activated in IBC 
(Lerebours et al., 2008; Van Laere et al., 2006). This constitutive NF-κB activation 
might be partly mediated through CIH and TNC. 
 
TNC is now becoming increasingly used as a diagnostic and prognostic marker for a 
number of different cancers (Ide et al., 2007; Ishihara, Yoshida, Tamaki, & Sakakura, 
1995; Tanaka et al., 2000). Also, it is the target of novel anti-cancer therapies. 
Several monoclonal antibodies have been developed that recognize tumor-specific 
TNC isoforms, hence targeting TNC in cancer but not in healthy tissue (Brack, 
Silacci, Birchler, & Neri, 2006). Some of these therapeutic antibodies have been 
examined in preclinical and clinical trials. One of these antibodies is the F16 antibody 
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that recognizes the A1 domain of TNC. Coupling the F16 antibody to interleukin-2 
(IL-2) targets IL-2 to the tumor where it attracts the immune system to eliminate the 
tumor cells. Preclinical studies revealed reasonable effects, especially in combination 
with cytotoxic drugs (Mårlind et al., 2008), and suggested applicability to human 
cancer patients. Indeed, first clinical trials have been performed (Catania et al., 
2015). Other attempts for the targeted delivery of radioisotopes or chemical agents to 
tumors include the generation of TNC specific aptamers (Daniels, Chen, Hicke, 
Swiderek, & Gold, 2003; Hicke et al., 2001). Further, a vaccination approach 
targeting several tumor specific antigens, including TNC domain C, is currently under 
investigation (Saupe et al., 2015). The development of TNC targeting therapies 
emphasizes the importance of TNC in cancer progression and hence in the treatment 
of cancer. Further understanding of its regulation on the transcriptional level might 
help to design strategies to prevent its induction during tumorigenesis.  
 
This thesis identifies CIH in mediating tumor promotive gene expression changes. It 
further emphasizes the importance of CIH and NF-κB in TNC regulation and also in 
the regulation of other pro-metastatic genes in an IBC cells line. It reveals a putative 
novel mechanism involved in inflammatory breast cancer aggressiveness.  
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